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Disclaimers: 
All material in this publication is in the public domain and may be used and reprinted without permission; 
citation as to source, however, is appreciated.  
References to non-CDC sites on the Internet are provided as a service to readers and do not constitute or imply 
endorsement of these organizations or their programs by CDC or the U.S. Department of Health and Human 
Services. CDC is not responsible for the content of these sites. URL addresses listed were current as of the date 
of publication.  
This report describes use of certain drugs and tests for some indications that do not reflect labeling approved by 
the Food and Drug Administration at the time of publication. Use of trade names and commercial sources is for 
identification only and does not imply endorsement by the U.S. Department of Health and Human Services.  
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III. DISCLOSURE OF POTENTIAL COMPETING INTEREST 
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involved in guidelines development and procedures for managing conflicts of interest, lists of names and 
affiliations of the nPEP guidelines development teams and consultants, and financial disclosures of potential 
competing interests.  
IV. SUMMARY 
The purpose of these guidelines is to provide health care providers in the United States with updated guidelines 
to the 2005 U.S. Department of Health and Human Services nonoccupational postexposure prophylaxis (nPEP) 
recommendations1 on the use of antiretroviral nPEP and other aspects of case management for persons with 
isolated exposure outside health care settings to blood, genital secretions, or other potentially infectious body 
fluids that might contain human immunodeficiency virus (HIV). The use of occupational PEP (oPEP) for case 
management for persons with possible HIV exposures occurring in health care settings are not addressed in this 
guideline; updated oPEP guidelines have been published separately.2  
IV-A. What Is New in This Update 
This update incorporates additional evidence regarding use of nonoccupational postexposure prophylaxis 
(nPEP) from animal studies, human observational studies, and consideration of new antiretroviral medications 
that were approved since the 2005 guidelines, some of which have improved tolerability. New features are 
inclusion of guidelines for the use of rapid antigen/antibody (Ag/Ab) combination HIV tests, for revised 
preferred and alternative 3-drug antiretroviral nPEP regimens, an updated schedule of laboratory evaluations of 
source and exposed persons, updated antimicrobial regimens for prophylaxis of sexually transmitted infections 
and hepatitis, and a suggested procedure for transitioning patients between nPEP and HIV preexposure 
prophylaxis (PrEP), as appropriate.  
IV-B. Summary of Guidelines 
• Health care providers should evaluate persons rapidly for nPEP when care is sought ≤ 72 hours after a 
potential nonoccupational exposure that presents a substantial risk for HIV acquisition.a [VI-A4] 
[VII-A2]b  
o All persons considered for nPEP should have determination of their HIV infection status by 
HIV testing, preferably by using rapid combined Ag/Ab, or antibody blood tests. [VII-A1] 
[VII-B1] 
o If rapid HIV blood test results are unavailable, and nPEP is otherwise indicated, it should be 
initiated without delay and can be discontinued if the patient is later determined to have HIV 
infection already or the source is determined not to have HIV infection. [VII-A1] 
                                                          
a See Figure 1. 
b Numbers in brackets refers readers to the section in these guidelines that provides the basis for the recommendation. 
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• nPEP is recommended when the source of the body fluids is known to be HIV-positive and the 
reported exposure presents a substantial risk for transmission. [VII-A]  
• nPEP is not recommended when the reported exposure presents no substantial risk of HIV 
transmission. [VII-A] 
• nPEP is not recommended when care is sought > 72 hours after potential exposure. [VI-A4] [VII-A] 
[VII-A2] 
• A case-by-case determination about the nPEP is recommended when the HIV infection status of the 
source of the body fluids is unknown and the reported exposure presents a substantial risk for 
transmission if the source did have HIV infection. [VII-A] 
• All persons offered nPEP should be prescribed a 28-day course of a 3-drug antiretroviral regimen.a 
[VII-B1] [VII-C] 
o The preferred regimen for otherwise healthy adults and adolescents 
 tenofovir disoproxil fumarate (tenofovir DF or TDF) (300 mg) with emtricitabine (200 
mg) once daily plus 
raltegravir (RAL) 400 mg twice daily or dolutegravir (DTG) 50 mg daily. [VI-A2ci] 
[VII-C] 
o Alternative regimen for otherwise healthy adults and adolescents is 
 tenofovir DF (300 mg) with emtricitabine (FTC) (200 mg) once daily plus 
darunavir (DRV) (800 mg) and ritonavira (RTV) (100 mg) once daily. [VII-C] 
o Regimens are also provided for children, persons with decreased renal function, and pregnant 
women (see Table 6). [VII-C] 
o Health care providers considering using antiretroviral regimens for nPEP other than those 
listed in these guidelines as preferred or alternative are encouraged to consult with other 
health care providers who have expertise in antiretroviral medication use for similar patients 
(e.g., children, pregnant women, or those with such comorbid conditions as impaired renal 
function). [VII-C] [VII-E2] 
• All persons evaluated for possible nPEP should be provided any indicated prevention, treatment, or 
supportive care for other exposure-associated health risks and conditions (e.g., bacterial sexually 
transmitted infections, traumatic injuries, hepatitis B virus and hepatitis C virus infection, or 
pregnancy). [VII] [VII-B3] [VII-B4] [VII-B5] [VII-D]  
• All persons who report behaviors or situations that place them at risk for frequently recurring HIV 
exposures (e.g., injection drug use, or sex without condoms) or who report receipt of ≥ 1 course of 
nPEP in the past year should be provided risk-reduction counseling and intervention services, 
including consideration of preexposure prophylaxis. [VII-E4] [VII-E5] 
                                                          
a Ritonavir is used in clinical practice as a pharmacokinetic enhancer to increase the trough concentration and prolong the half-life of 
darunavir and other protease inhibitors; it was not considered an additional drug when enumerating drugs in a regimen.  
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V. INTRODUCTION  
The most effective methods for preventing human immunodeficiency virus (HIV) infection are those that 
protect against exposure. Antiretroviral therapy cannot replace behaviors that help avoid HIV exposure (e.g., 
sexual abstinence, sex only in a mutually monogamous relationship with an HIV-uninfected partner, consistent 
and correct condom use, abstinence from injection drug use, and consistent use of sterile equipment by those 
unable to cease injection drug use). Provision of antiretroviral medication after isolated sexual, injection drug 
use, or other nonoccupational HIV exposure, known as nonoccupational postexposure prophylaxis (nPEP), is 
less effective at preventing HIV infection than avoiding exposure.  
In 2005, the U.S. Department of Health and Human Services (DHHS) released its first recommendations for 
nPEP use to reduce the risk for HIV infection after nonoccupational exposures to blood, genital secretions, and 
other body fluids that might contain HIV.1 In 2012, updated guidelines on the use of occupational PEP (oPEP) 
for case management for persons with possible HIV exposures occurring in health care settings were published 
and are not addressed in this guideline.2 Other organizations, including health departments, professional medical 
societies, and medical institutions, have developed guidelines, recommendations, and protocols for nPEP 
delivered to adults and children.3-10 
This document updates the 2005 DHHS nPEP recommendations in response to new information regarding 
clinical experience for delivering nPEP, including using newer antiretroviral regimens and their side-effect 
profiles and cost-effectiveness of nPEP to prevent HIV infection for different exposure types. We describe in 
more detail the goals for the new guidelines, funding source of the guidelines, persons involved in guidelines 
development, definition of competing interest for persons involved in guidelines development and procedures 
for managing competing interest (Appendix 1A).  
CDC scientists selected nPEP subject matter experts from the Food and Drug Administration (FDA), the 
National Institutes of Health (NIH), hospitals, clinics, health departments, and professional medical societies to 
participate as panelists to discuss recent developments in nPEP practice by CDC teleconferences in December 
2011, and April 2012 (Appendix 1B). Any potential conflicts of interests reported by persons involved in 
developing the guidelines and the determination made for each of those potential conflicts are listed in 
Appendix 1C.  
A working group of CDC HIV prevention scientists and other CDC scientists with expertise pertinent to the 
nPEP guidelines conducted nPEP-related systematic literature reviews. Appendix 2 summarizes the methods 
used to conduct that review, including databases queried, topics addressed, search terms, search dates, and any 
limitations placed on the searches (i.e., language, country, population, and study type). All studies identified 
through the literature search were reviewed and included in the body of evidence. Appendix 3 includes a 
summary of the key observational and case studies among humans that comprise the main body of evidence.  
These nPEP guidelines are not applicable for occupational exposures to HIV; however, we attempted to 
standardize the selection of preferred drugs for nPEP and occupational postexposure prophylaxis (oPEP).2 
These guidelines also do not apply to continuous daily oral antiretroviral prophylaxis that is initiated before 
potential exposures to HIV as a means of reducing the risk for HIV infection among persons at high risk for its 
sexual acquisition (preexposure prophylaxis or PrEP11).  
Among the limitations of these guidelines is that they are based on a historical case-control study related to 
occupational PEP among hospital workers, observational and case studies examining nPEP’s effectiveness 
among humans, animal studies related to PEP’s efficacy among primates, and expert opinion on clinical 
practice among humans related to nPEP. Because of concerns about the ethics and feasibility of conducting 
large-scale prospective randomized placebo-controlled nPEP clinical trials, no such studies have been 
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conducted. Additionally, although nPEP failures were rare in the observational studies we reviewed, those 
studies often have inadequate follow-up testing rates for HIV infection; therefore, nPEP failures might be 
underestimated. Because these guidelines represent an update of previous guidelines about a now established 
clinical practice, we elected not to use a formal grading scheme to indicate the strength of supporting evidence.  
VI. EVIDENCE REVIEW 
VI-A. Possible Effectiveness of nPEP  
No randomized, placebo-controlled clinical trial of nPEP has been conducted. However, data relevant to nPEP 
guidelines are available from animal transmission models, perinatal clinical trials, observational studies of 
health care workers receiving prophylaxis after occupational exposures, and observational and case studies of 
nPEP use. Although the working group mainly systematically reviewed studies conducted after 2005 through 
July 2015, we also include findings from seminal studies published before 2005 that help define key aspects of 
nPEP guidelines. Newer data reviewed in this document continue to support the assertion that nPEP initiated 
soon after exposure and continued for 28 days with sufficient medication adherence can reduce the risk for 
acquiring HIV infection after nonoccupational exposures. 
V1-A1. oPEP Studies 
A case-control study demonstrating an 81% (95% confidence interval [CI] = 48%–94%) reduction in the odds 
of HIV transmission among health care workers with percutaneous exposure to HIV who received zidovudine 
(ZDV) prophylaxis was the first to describe the efficacy of oPEP.12 Because of the ethical and operational 
challenges, no randomized controlled trials have been conducted to test the efficacy of nPEP directly. In the 
absence of a randomized controlled trial for nPEP, this case-control study reports the strongest evidence of 
benefit of antiretroviral prophylaxis initiated after HIV exposure among humans.  
V1-A2. Observational and Case Studies of nPEP  
The following is a synopsis of domestic and international observational studies and case reports that have been 
published since the 2005 U.S. nPEP guidelines were issued. In the majority of studies, failure of nPEP, defined 
as HIV seroconversion despite taking nPEP as recommended, was typically confirmed by a seronegative HIV 
enzyme-linked immunosorbent assay (ELISA) at baseline visit, followed by a positive ELISA and Western blot 
or indirect fluorescent antibody (IFA) during a follow-up visit.  
VI-A2a. Men Who Have Sex with Men 
Based on 1 case report13 and 6 studies14-19 reporting results exclusively or separately among men who have sex 
with men (MSM), 49 seroconversions were reported after nPEP use. The case report from Italy described an 
nPEP failure in an MSM despite self-reported 100% adherence to his 3-drug medication regimen consisting of 
ZDV, lamivudine (3TC), and indinavir (IDV) and denial of ongoing HIV risk transmission behaviors after 
completing nPEP; concomitant hepatitis C virus (HCV) seroconversion was also diagnosed.13 In the 6 studies, 
48 of 1,535 (31.3 seroconverions/1,000 persons) MSM participants became HIV infected despite nPEP use. At 
least 40 of the 48 seroconversions likely resulted from ongoing risk behavior after completing nPEP. Thirty-five 
of these 40 seroconversions occurred ≥ 180 days subsequent to nPEP initiation and are unlikely to constitute 
nPEP failures.16,18 The remaining 8 seroconverters among 1,535 MSM participants (5.2 seroconverions/1,000 
persons) may be classified as potential nPEP failures. This included 1 recipient with an indeterminate HIV test 
result and isolation of an M184 mutation resistant virus on the last day of his 28-day regimen despite initiating 
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nPEP ≤ 48 hours after exposure,20 indicating that seroconversion was occurring during the 28-day period of 
nPEP administration. Another 4 patients seroconverted at 91 days, 133 days, 160 days, and 168 days after nPEP 
initiation, including 3 who reported completing the 28-day regimen; however, there was no description of the 
presence or lack of ongoing sexual risk behaviors after nPEP completion.18 Among the remaining 3 men who 
seroconverted after taking nPEP, taking nPEP was not associated with any suggestion of change in 
seroconversion risk, although no information was reported regarding the nPEP regimen prescribed, adherence to 
nPEP, delay in nPEP initiation or timing of HIV-positive results.15  
In a 2-year prospective study in Brazil, investigators provided 200 seronegative MSM at high risk with 
education regarding nPEP and a 4-day starter pack with instructions to initiate its use for a suspected eligible 
exposure.16 A follow-up 24-day pack (to complete a 28-day course) was provided only for those men with 
eligible exposures. Sixty-eight of 200 MSM initiated nPEP. Adherence to nPEP medications was estimated on 
the basis of questions at the 28-day visit and remaining pill counts. The entire 28-day nPEP regimen was 
completed by 89% of men with eligible exposures including 1 participant who seroconverted. Ten of 11 
seroconversions occurred among men who did not initiate nPEP.16  
VI-A2b. Sexual Assault  
VI-A2bi. General Population (all ages). Globally, 3 systematic reviews20-22 and 1 prospective cohort 
study23 spanning childhood through adulthood reported wide-ranging proportions of participants being eligible 
for nPEP (range, 6%–94%), being offered nPEP (range, 5%–94%), accepting nPEP (range, 4%–100%), or 
completing nPEP (range, 9%–65%). Among the 3 systematic reviews, none reported HIV screening results or 
the number of nPEP failures.20-22 
VI-A2bii. Adults and Adolescents. Although nPEP use for sexual assault survivors has been widely 
encouraged both in the United States and elsewhere,24-27 documented cases of HIV infection resulting from 
sexual assault of women or men rarely have been published.25,28,29 Of 5 individual retrospective studies of nPEP 
limited to adult and/or adolescent sexual assault survivors that the working group reviewed, 3 reported no 
seroconversions at baseline or at follow-up among those sexual assault survivors who completed nPEP,30-32 and 
2 did not report any information about HIV screening results or the number of nPEP failures.33,34 
VI-A2biii. Children and Adolescents. Studies of nPEP also have focused on children or adolescents 
evaluated for sexual assault. In a pooled analysis based on 10 studies of 8,336 children or adolescents evaluated 
for sexual assault or abuse, at least 1,362 were determined to be nPEP eligible. Twenty-four of the remaining 
6,974 (3.4 seroconversions/1,000 persons) children or adolescents who were not eligible for nPEP were found 
to be HIV infected at baseline testing.35-44 Among 672 children or adolescents reported to have been offered 
nPEP, 472 were known to have initiated nPEP, and 126 were reported to have completed a 28-day nPEP course. 
No new HIV infections were documented among these 472 (0.0 seroconversions/1,000 persons) 
children/adolescents in the pooled analysis who initiated nPEP. New HIV infections might have been 
underestimated as return rates for children or adolescents attending at least 1 follow-up visit during which an 
HIV test might have been conducted after initiating nPEP ranged from 10%40 to 76%.44 
VI-A2c. Mixed or Other Populations 
VI-A2ci. Mixed populations. Eighteen studies, including 9 international studies45-54 and 9 domestic 
studies55-63 examined multiple routes of HIV risk exposure among adults, adolescents, and children with sexual 
and nonsexual exposures, including consensual sexual relations, sexual assault, injection drug use, and 
needlestick exposures.  
Fifteen of the 19 studies reported both the number of participants who completed 28 days of nPEP and the 
number of participants who HIV seroconverted after initiating nPEP.46-58,62,63 In these 15 studies, 2,209 
participants completed 28 days of nPEP, of whom, at least 19 individuals HIV seroconverted,45-48,52,54,56,62,63 but 
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only 1 seroconversion47 (8.6/1,000) was attributed to nPEP failure. This seroconversion occurred 6 weeks after 
nPEP initiation in a sexually assaulted female who presented ≤ 4 hours after assault and completed nPEP.47 She 
had a positive HIV RNA polymerase chain reaction (PCR) test but no confirmatory HIV ELISA test 
documented during the 5–6 week follow-up HIV testing period after initiating nPEP. Among the other 18 
seroconversions that occurred during follow-up HIV testing among participants who completed 28 days of 
nPEP, 5 occurred ≥6 months after nPEP completion and were likely associated with ongoing sexual risk 
behavior after nPEP completion.45,54 One seroconversion occurred after a participant reported poor adherence to 
nPEP, ongoing sexual risk behavior, and multiple nPEP courses after the initial course of nPEP, however, the 
timing of seroconversion was not clearly specified.63 One seroconversion occurred in an MSM presenting with 
acute retroviral syndrome 3 weeks after condomless anal sex with an anonymous partner and no receipt of 
nPEP.48 One seroconversion occurred in a woman during the 6-month follow-up period after completing nPEP 
and it was attributed to ongoing sharing of injection drug use equipment.48 One seroconversion occurred in a 
patient who started nPEP > 72 hours after a high-risk exposure.46 Additional seroconversions occurred at 
various time periods after initiation of nPEP without detailed information about ongoing sexual exposure or 
adherence to nPEP (2 and 5 months [n=2 participants]62; 3 and 6 months [n=2 participants]52; 5 months [n=1 
participant]62; and 12 months [n=1 participant]).62 Among 3 participants who seroconverted while taking or 
shortly after taking ZDV-containing nPEP regimens, there was a lack of information about ongoing sexual 
exposure or detailed information about strict adherence to the full 28-day nPEP regimen.56 However, only 
33.8%–42.1% of all patients who were administered ZDV-containing nPEP regimens in this study completed 
their regimens as prescribed.56  
In the remaining 4 of 19 studies, 2 studies did not report rates of HIVseroconversion59,60 and 2 studies did not 
report rates of completion of the 28-day nPEP regimen,45,61 including a study that reported 7 seroconversions 
that occurred at unspecified time periods during the 6 months after nPEP initiation among 649 users of 
nPEP.61Of all nPEP clients in this study, 18.5% had previously used nPEP between 1 and 5 times.61  
In 3 domestic studies, participants who were administered tenofovir (TDF)-containing nPEP regimens were 
substantially more likely than historical control subjects in studies consisting of ZDV-containing regimens to 
complete their prophylaxis as prescribed and less likely to experience common side effects.49,56,57,60 In two 
studies, the highest completion rates were observed for the TDF-3TC (87.5%) and TDF-emtricitabine (FTC) 
(72.7%) arms followed by the TDF-FTC-raltegravir (RAL) (57%) and ZDV-3TC-3rd drug arms (the 3rd drug 
was mainly a protease inhibitor [PI]) (38.8 %).57 In addition to the 57% of patients who completed all 3 drugs of 
the TDF-FTC-RAL arm, 27% of patients took their TDF-FTC and first RAL dose daily, but sometimes missed 
the second dose of RAL.57 In another study, the completion rates were highest in the TDF-FTC-ritonavir 
(RTV)-boosted lopinavir (LPV/r) arm (88.3%) compared with the TDF-3TC-RTV-boosted atazanavir (ATV/r) 
arm (79%), ZDV-3TC-LPV/r arm (77.5%), or ZDV-3TC-nelfinavir (NFV) arm (65.5%).49 In the last domestic 
study, TDF-containing compared with ZDV-containing regimens were associated with significantly higher 
completion rates in the bivariate analysis (OR 2.80 [95% CI = 1.69–1.18]) but not in the multivariate analysis 
(OR 1.96 [95% CI = 0.73–5.28]).60  
VI-A2cii. Other Populations. Data for 438 persons with unintentional nonoccupational needlestick or 
other sharps exposures described in 7 published reports were reviewed, including data for 417 children and 21 
adults.64-70 Childhood and adolescent exposures were characterized as community-acquired exposures occurring 
in public outdoor places (e.g., playgrounds, parks, or beaches) or by reaching into needle disposal boxes at 
home or in a hospital. Adult exposures were often similar to occupational exposures occurring while handling 
needles or disposing of needles in a sharps container. In all cases, the HIV status of the source person was 
unknown except in 1 report64 involving multiple percutaneous exposures with lancets among 21 children while 
playing with discarded needles in a playground. Some of the lancets had been used multiple times to stick 
different children. One of the children stuck with a lancet was known to be HIV infected before the incident, not 
receiving antiretroviral therapy, and documented to have an HIV-1 plasma viral load of 5,250,000 copies/mL; 
the other 20 children were considered potentially exposed to HIV.64 Additionally, in 1 of the studies, 2 children 
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were hepatitis B surface antigen (HBsAg)-positive at baseline before starting prophylaxis.66 Among 155 
children offered nPEP, 149 accepted and initiated nPEP, and 93 completed their 28-day nPEP course.64-70 
Antiretroviral prophylaxis with either ZDV and 3TC or ZDV, 3TC plus a PI (IDV, NFV, LPV/r) or a non-
nucleoside reverse transcriptase inhibitor (NNRTI) (nevirapine [NVP]) was used for those 149 children or 
adults accepting and initiating nPEP. No seroconversions for HIV, hepatitis B virus (HBV), or HCV were 
reported among those receiving or not receiving nPEP.64-70  
In the case report of a 12-year old girl in Saudi Arabia with sickle-cell disease who was inadvertently transfused 
with a large volume of packed red blood cells, the use of a 13-week, 4-drug nPEP regimen of TDF, FTC, 
ritonavir-boosted darunavir (DRV/r) (later changed to LPV) and RAL resulted in loss of presence of detectable 
HIV-1 antibodies.71 No HIV-1 DNA or plasma HIV-1 RNA was detected by PCR testing during the 8-month 
follow-up period. 
VI-A3. Postnatal Prophylaxis of Infants Born to HIV-infected Mothers 
Data regarding the efficacy of infant PEP to prevent mother-to-child HIV transmission provides only limited, 
indirect information about the efficacy of antiretroviral medications for nPEP. Postpartum antiretroviral 
prophylaxis is designed to prevent infection after contact of mucosal surfaces (ocular, oral, rectal, or urethral) or 
broken skin in the infant with maternal blood or other fluids that are present at time of labor and delivery, 
especially during vaginal births. Trials in which the infant was provided postpartum prophylaxis but the mother 
received neither prepartum or intrapartum antiretroviral prophylaxis provide the most relevant indirect data 
regarding nPEP after exposure to a source who did not have suppressed viral load secondary to antiretroviral 
therapy. Although a combination of prophylaxis during the prenatal, intrapartum, and postpartum periods offers 
the most effective reduction of perinatal transmission, postpartum prophylaxis alone also offers reduction.72-75 
A randomized open-label clinical trial of antiretrovirals provided to infants born to breastfeeding HIV-infected 
women demonstrated an overall reduction in postnatal HIV infection at 14 weeks (the end of the period of 
prophylaxis) by approximately 70% (95% CI unreported). The trial compared a control group receiving a short-
arm postnatal prophylaxis regimen and 2 comparison groups, each receiving different extended-arm postnatal 
prophylaxis regimens.76 The control group received the short-arm regimen consisting of single-dose NVP plus 
1-week ZDV and the 2 comparison groups received the control regimen and either 1) extended daily NVP for 
14 weeks or 2) extended daily NVP and ZDV for 14 weeks. The corresponding HIV infection rates at 14 weeks 
were 8.5% in the control group, and 2.6% and 2.5% in the 2 extended arms comparison groups, respectively.  
An observational study documented a potential effect of ZDV prophylaxis initially started postnatally compared 
with the prepartum and intrapartum periods. A review of 939 medical records of HIV-exposed infants in New 
York State indicated that the later the prophylaxis was started after the prepartum period, the higher the 
likelihood of perinatal transmission and that a benefit existed to postnatal prophylaxis alone (without maternal 
intrapartum or prepartum medication). Perinatal prophylaxis started during the prepartum, intrapartum, early 
postpartum (≤ 48 hours after birth), and late postpartum (3 days–42 days) periods resulted in corresponding 
transmission rates of 6.1%, 10.0%, 9.3%, and 18.4%, respectively.77 A perinatal transmission rate of 31.6% was 
observed when no perinatal prophylaxis was provided; the study included data from patients who had 
pregnancies early in the epidemic when HIV perinatal prophylaxis was first being implemented, and it was 
uncertain whether using intrapartum and/or postnatal prophylaxis alone was beneficial among mothers without 
prenatal care.  
VI-A4. Animal Studies 
Macaque models have been used to assess potential PEP efficacy. These studies examined artificial exposures 
to simian immunodeficiency virus (SIV) which varied by modes of exposure, virus innocula, and drug 
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regimens. The parameters imposed by those animal studies might not reflect human viral exposures and drug 
exposures, and those differences should be considered when interpreting their findings. Nevertheless, macaque 
models have provided important proof-of-concept data regarding PEP efficacy. More recent animal studies have 
tested the effectiveness of newer antiretrovirals and alternate routes of PEP administration. Subcutaneous 
tenofovir was reported to block SIV infection after intravenous challenge among long-tailed macaques if 
initiated ≤ 24 hours after exposure and continued for 28 days.78 All 10 macaques initiated on PEP at 4 or 24 
hours post inoculation were documented to be SIV-uninfected at 36–56 weeks post inoculation compared with 
all 10 macaques that failed to receive any prophylaxis and became SIV infected within 20–36 weeks post-
inoculation. In a study of 24 macaques, TDF was less effective if initiated 48 or 72 hours post-exposure or if 
continued for only 3 or 10 days.79 In contrast, all 11 macaques became SIV infected in a study involving 3 
control macaques receiving no prophylaxis and 8 macaques receiving a combination of ZDV, 3TC, and IDV 
administered orally through nasogastric catheter after intravenous virus inoculation at 4 or 72 hours post-SIV 
inoculation.80 High virus innocula and drug exposures that are lower than those achieved among humans as a 
result of inadequate interspecies adjustment of drug dosing might have contributed to the lack of protection 
reported for that study. However, a macaque study designed to model nPEP for vaginal HIV exposure 
demonstrated that a combination of ZDV, 3TC and a high dose of IDV protected 4 of 6 animals from vaginal 
SIV infection when initiated ≤ 4 hours after vaginal exposure and continued for 28 days, whereas 6 of 6 animals 
in the control group receiving a placebo became SIV infected.81 In another study, after 20 vaginal simian/human 
immunodeficiency virus infection (SHIV) challenges and a 10-week follow-up period, 5 of 6 macaques were 
protected when treated with topically applied gel containing 1% RAL 3 hours after each virus exposure 
compared with none of four macaques treated with placebo gel.82 Likewise, macaques administered 
subcutaneous TDF for 28 days, beginning 12 hours (4 animals) or 36 hours (4 animals) after vaginal HIV-2 
exposure, were protected from infection. Three of 4 animals treated 72 hours after exposure were also 
protected.83 Three of 4 untreated animals in the control group became infected with HIV-2. Overall, data from 
these macaque studies demonstrate that PEP might be effective among humans if initiated ≤ 72 hours and 
continued daily for 28 days. In a systematic review and meta-analysis of 25 nonhuman primate studies, 
including rhesus macaques in10 studies and cynomolgus monkeys in 5 studies, use of PEP was associated with 
an 89% lower risk of seroconversion compared with nonhuman primates who did not use PEP. Also, use of 
tenofovir compared with other drugs was associated with lower seroconversion.84  
VI-B. Possible Risks Associated with nPEP  
Concerns regarding potential risks associated with nPEP as a clinical HIV prevention intervention include the 
occurrence of serious adverse effects from the short-term use of antiretroviral medications by otherwise healthy 
persons without HIV infection, and potential selection for drug-resistant strains of virus among those who 
become HIV infected despite nPEP use (particularly if medication adherence is inconsistent during the 28-day 
course or if the source transmits resistant virus). An additional concern is that persons engaging in consensual 
sex or nonsterile injection drug use may rely solely on PEP instead of adopting more long-term risk-reduction 
behaviors such as safer sexual and drug-injecting behaviors.  
VI-B1. Antiretroviral Side Effects and Toxicity  
In a meta-analysis20 of 24 nPEP-related studies, including 23 cohort studies and 1 randomized clinical trial 
(behavioral intervention to improve nPEP adherence), of 2,166 sexually assaulted persons, clinicians prescribed 
2-drug regimens,36,38,40,42,85-88 3-drug regimens,23,31,58,89-92 2- and 3-drug regimens,30,32,50,93,94 or an unknown 
number of drugs.46,95-97 ZDV was a part of all the regimens and all 2-drug regimens contained ZDV and 3TC, 
except 1 study in which ZDV and zalcitabine were prescribed.88 Antiretrovirals provided as a part of 3-drug 
regimens included ZDV, 3TC, NFV, IDV, LPV/r, NVP, efavirenz (EFV), or co-formulated FTC/TDF with co-
formulated LPV/r. Nausea, vomiting, diarrhea, and fatigue were the most commonly reported side effects.20 
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Serious side effects have been reported occasionally (e.g., nephrolithiasis and hepatitis) in the literature.98-100 
Rarely, severe hepatotoxicity has been observed among patients administered NVP-containing regimens for 
both oPEP and nPEP, including a female health care worker who required a liver transplantation after taking 
oPEP101; therefore, CDC advises against use of NVP forPEP.1,99 Also, since January 2001, product labeling for 
NVP states that using it as part of a PEP regimen is contraindicated.102 
A retrospective study in western Kenya involved 296 patients who were eligible for and initiated nPEP, 
including 104 who completed a 28-day course of nPEP; patients received either stavudine (d4T), 3TC and NVP 
or ZDV, 3TC, and LPV/r.47 Neither the proportion of patients reporting side effects (14% [LPV-containing arm] 
and 21% [NVP-containing arm]) nor antiretroviral therapy completion rates differed substantially between the 2 
arms. The most commonly reported side effects included epigastric pain, skin rash, and nausea among patients 
receiving NVP-containing regimens and diarrhea, dizziness, and epigastric pain among those receiving LPV/r-
containing regimens. However, 1 hepatitis-related death of a sexual assault survivor taking a NVP-containing 
regimen prompted investigators to change to a new PEP regimen containing ZDV, 3TC, and LPV/r. Inclusion 
of NVP and d4T were initially included in nPEP regimens because of availability and cost but were 
discontinued in 2005 as a result of adverse events and toxicities among healthy patients. This change was also 
influenced by a black box warning in the drug labeling for NVP describing increased toxicity among patients on 
NVP with higher CD4 T lymphocyte (CD4) cell counts. 
Commonly used medications in the observational studies of nPEP published after 2005 included ZDV, 3TC, 
LPV/r, TDF, FTC, and RAL. The majority of regimens involved using 3 drugs (range, 2–4 drugs) with a daily 
2-pill burden (range, 1–3 pills). The side-effect profile that included fatigue, nausea, headache, diarrhea, and 
other gastrointestinal complaints was similar across studies of MSM having mainly consensual sex and studies 
of sexual assault survivors, including mainly women, children, and a limited proportion of men.20,23,31,44,55-57,103 
Two trials, including a total of 602 participants, compared TDF- versus ZDV-containing nPEP regimens; both 
reported better medication tolerability among participants taking TDF-containing regimens.49,56 Another study 
reported fewer side effects among 100 adult participants prescribed a 3-drug nPEP regimen that included RAL, 
TDF, and TDF compared to historical controls using a 3-drug PEP regimen including ZDV, 3TC, and a RTV-
boosted PI.57  
In an open-label, nonrandomized, prospective cohort study comparing RAL-FTC-TDF in 86 MSM and FTC-
TDF in 34 MSM, 92% and 91% of participants completed 28 days of treatment, respectively, with mean 
adherences of 89% and 90%, respectively.17 Use of RAL rather than a PI was associated with the avoidance of 8 
prescribed drug, and 37 potential illicit drug, interactions. However, in the RAL arm, 8 recipients (9%) 
developed mild myalgias, and 4 recipients developed grade 4 elevations in creatinine kinase. Both the myalgias 
and creatinine kinase elevations improved to grade 2 or less by week 4 without RAL discontinuation.  
Among 100 MSM in an open-label, single-arm study at 2 public health clinics and 2 hospital EDs in urban areas 
in Australia, a once daily 28-day nPEP single-pill combination regimen of FTC-rilpivirine (RPV)-TDF was well 
tolerated with 98.5% adherence by self-report and 92% completion of the 28-day regimen.19 However, within 1 
week of completing nPEP, 1 patient developed acute abdominal pain, vomiting, and grade 4 laboratory evidence 
of acute pancreatitis (lipase 872 IU/L). The pancreatitis resolved ≤ 21 days without need for hospitalization.19  
In a 2-arm open label randomized multicenter clinical trial in EDs in 6 urban hospitals in Barcelona, Spain, 
comparing ZDV/3TC + LPV/r with ZDV/3TC + atazanavir (ATV), 64% of nPEP recipients in both arms 
completed the 28-day course and 92% of patients reported taking > 90% of scheduled doses (without difference 
between arms).53 Adverse events were reported in 46% of patients overall (49%, LPV/r arm; 43%, ATV arm). 
Gastrointestinal problems were more common in the LPV/r arm. 
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A pooled series of case reports revealed that 142 (67%; range, 0%–99%) of 213 children and adolescents who 
initiated nPEP and who had ≥1 follow-up visit, reported adverse effects and 139 of 465 (30%; range, 0%–
64.7%) children and adolescents who initiated nPEP, completed their course of nPEP.32,35-44 Most commonly 
reported nPEP regimens included ZDV + 3TC or ZDV + 3TC + (NFV or IDV or LPV/r). Most common 
adverse events among the 213 participants included nausea (n = 83; 39%), fatigue (n = 58; 27%), vomiting (n = 
38; 18%), headache (n = 26; 12%), diarrhea (n = 25; 12%), and abdominal pain (n = 15; 7%). 
V1-B2. Selection of Resistant Virus  
In instances where nPEP fails to prevent infection, selection of resistant virus by the antiretroviral drugs is 
theoretically possible. However, because of the paucity of resistance testing in documented nPEP failures, the 
likelihood of resistance occurring is unknown.  
A case report from Brazil documented a 3TC-resistance mutation on day 28 of therapy in a man treated with 
ZDV and 3TC who subsequently underwent HIV seroconversion.16 Although the patient was noted to have 
taken nPEP, detailed information regarding adherence was unreported. Because the source-person could not be 
tested, whether the mutation was present at the time of transmission or whether it emerged during nPEP use is 
unknown. 
Rationale for the concern regarding acquiring resistant virus from the exposure that leads to nPEP prescription 
includes data from an international meta-analysis of 287 published studies of transmitted HIV-1 drug resistance 
among 50,870 individuals during March 1, 2000–December 31, 2013, including 27 studies and 9,283 
individuals from North America.104 The study-level estimate of transmitted drug resistance in North America 
was 11.5% (resistance to any antiretroviral drug class), 5.8% (resistance to NRTIs), 4.5% (resistance to 
NNRTIs, and 3.0% (resistance to PIs). 
VI-B3. Effects of nPEP on Risk Behaviors  
The majority of studies examining the association between use and availability of nPEP and sexual risk 
behaviors during or after its use have been conducted in developed countries, primarily among MSM; no studies 
related to risk compensation were conducted among persons with injection-related risk factors.14,16,105-111 The 
majority of these studies did not report increases in high-risk sexual behaviors after receipt of nPEP14,16,106,110,111 
and participants sometimes reported a decrease in sexual risk-taking behavior.16,106 However, in 3 studies, nPEP 
users were more likely than persons who did not use nPEP to report having multiple partners and engaging in 
condomless receptive or insertive anal sex with HIV-infected partners or partners with unknown serostatus after 
completing nPEP.14,108,110 In 2 of these studies, nPEP users were also more likely to subsequently become HIV 
infected than patients who did not use nPEP.108,110 During 2000–2009 in the Amsterdam Cohort Study, MSM 
who were prescribed nPEP, compared with a reference cohort of MSM, had an incidence of HIV infection 
approximately 4 times as high (6.4 versus 1.6/100 person-years).108 During 2001–2007, MSM in a community 
cohort study in Sydney, Australia reported continued, but not increased, high-risk sexual behaviors among 
nPEP users; more specifically, no change in sexual behavior was reported at 6 months after 154 incident nPEP 
uses and after ≥18 months for 89 incident nPEP uses. Among those MSM who received nPEP, the hazard ratio 
of subsequent HIV infection was 2.67 (95% CI = 1.40, 5.08).110 The authors did not attribute this elevated risk 
for HIV seroconversion among users of nPEP to nPEP failure but rather to a documented higher prevalence of 
condomless anal intercourse (CAI) with HIV-infected partners among users of nPEP, compared with persons 
who did not use nPEP. In summary, users of nPEP, compared with participants who did not use nPEP had a 
continued higher prevalence of ongoing CAI with HIV-infected persons resulting in a greater likelihood of HIV 
seroconversion during all periods, especially after completing nPEP. In another study, repeated courses of nPEP 
were unassociated with risk for subsequent HIV infection.45 In a study of 99 patients who attended a clinic in 
Toronto to be evaluated for nPEP during January 1, 2013–September 30, 2014, 31 (31%) met CDC criteria for 
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PrEP initiation.112 PrEP candidacy in this study was associated with sexual exposure to HIV, prior nPEP use, 
and lack of drug insurance. Those studies14,108,110,112 demonstrate that certain nPEP users with ongoing high-risk 
sexual behaviors might need additional behavioral and biomedical prevention interventions, including PrEP, 
instead of nPEP.11,113  
One U.S.-based study among 89 MSM that examined risk behavior during the 28-day course of nPEP reported 
that among participants, 21% reported having insertive or receptive CAI, and 43% reported engaging with ≥ 1 
partner known to be HIV-positive or of unknown serostatus (i.e., a high-risk partner).105 Ninety-four percent of 
participants reporting having high-risk partners also reported having insertive or receptive anal intercourse. Of 
participants with high-risk partners and who practiced insertive or receptive anal intercourse, 26% reported CAI 
with their high-risk partner while receiving nPEP. The strongest predictor of CAI during nPEP in that study was 
HIV engagement, defined as receiving services from an HIV-related organization, donating money to or 
volunteering for an HIV-related cause, or reading HIV-related magazines and online sites. A nearly 5-fold 
chance of reporting condomless sex with a high-risk partner during nPEP was associated with each standard 
deviation increase in HIV engagement (OR 4.7 [95% CI = 1.3–17.04]). Investigators hypothesized that persons 
who are more involved with HIV-related services or organizations might be more informed about the 
effectiveness of nPEP and more likely to perceive themselves to be at less risk for HIV transmission while 
receiving nPEP and therefore more likely to have CAI.105  
Awareness of nPEP availability, defined as general knowledge of availability of nPEP as a tool for preventing 
HIV infection after a potential HIV exposure107 or nPEP use more than once in 5 years,103 was associated with 
condomless sex among MSM.103,107 Additionally, a longitudinal study of MSM in the Netherlands reported no 
associations existed between any nPEP-related beliefs (e.g., perceiving less HIV or acquired immunodeficiency 
syndrome (AIDS) threat, given the availability of nPEP, or perceiving high effectiveness of nPEP in preventing 
HIV) and the incidence of sexually transmitted infections (STIs) or new HIV infection.109  
VI-C. Antiretroviral Use During Pregnancy  
No trials have been conducted to evaluate use or the maternal or fetal health effects of short-term (i.e., 28-day) 
antiretroviral use as nPEP among pregnant women without HIV infection. However, clinical trials have been 
conducted and extensive observational data exist regarding use of specific antiretrovirals during pregnancy 
among HIV-infected women both when initiated as treatment for health benefits to the women and when 
initiated to reduce mother-to-child HIV transmission. Although duration of antiretroviral use during pregnancy 
has varied in these trials, it often spans months of pregnancy. Only ZDV is specifically approved for use in 
pregnancy, but as a result of data from clinical trials, other antiretroviral drugs have been reported to have short-
term safety for pregnant women and their fetuses, and therefore can be considered for nPEP in women who are 
or who might become pregnant. See Recommendations for Use of Antiretroviral Drugs in Pregnant HIV-1-
Infected Women for Maternal Health and Interventions to Reduce Perinatal HIV Transmission in the United 
States for information regarding use of specific antiretrovirals during pregnancy.114 Additionally, results from 
ongoing surveillance of major teratogenic effects related to antiretroviral use during pregnancy are described in 
the Antiretroviral Pregnancy Registry International Interim Report every 6 months.115 
Certain antiretrovirals have been associated with severe side effects, toxicity, potential for teratogenicity, or 
other untoward effects among pregnant and non-pregnant women with HIV infection114 and therefore are not 
recommended for nPEP use (see section VII-F2b. Pregnant Women and Women of Childbearing Potential for a 
list of antiretroviral medications that should not be used for nPEP in pregnant women). These include EFV, 
NVP, and d4T plus didanosine (DDI).114 Using IDV without RTV-boosting demonstrated altered drug 
metabolism during pregnancy.116,117 No severe side effects, toxicity, or adverse pregnancy outcomes have been 
reported to occur among HIV-uninfected women taking antiretrovirals for oPEP or nPEP. 
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Reports are conflicting regarding whether an association exists of substantial malformations with use of EFV 
during the first trimester among humans. Studies using cynomolgus monkeys reported a potential association 
between neurologic congenital malformations and first-trimester use of EFV.118 Although case reports exist of 
neurologic defects among infants of women receiving EFV,119,120 no elevated risk for overall congenital 
malformations associated with first-trimester EFV exposure have been reported in either prospectively reported 
pregnancies from the Antiretroviral Pregnancy Registry115 or from a meta-analysis of 23 studies with birth 
outcomes from 2,026 live births among women receiving EFV during the first trimester.121  
HIV-infected pregnant women receiving combination antiretroviral regimens that included NVP have been 
reported to suffer severe hepatic adverse events, including death. However, whether pregnancy increases the 
risk for hepatotoxic events associated with NVP therapy is unknown. Use of NVP in HIV-infected women 
(regardless of pregnancy status) with high CD4 counts > 250 cells/mm^3102 or elevated transaminase levels at 
baseline122 has been associated with potentially life-threatening rash and hepatotoxicity. NVP use in 3 HIV-
infected women with CD4 counts < 100 cells/mm^3 at baseline has been associated with death among those also 
taking anti-tuberculosis therapy.122  
Among antiretroviral medication combinations no longer recommended, regimens containing d4T with DDI 
have been associated with severe maternal lactic acidosis among pregnant HIV-infected women,123,124 including 
severe necrotic pancreatic and hepatic steatosis and necrotic cellulitis of the abdominal wall in 1 woman,123 
1 fetal demise (normal for gestational age) at 38 weeks gestation,124 and 1 postnatal death at age 2 weeks in a 
1,000 gram infant with trisomy 18.123 Additionally, using IDV without RTV-boosting during pregnancy results 
in substantially lower antepartum exposures of IDV, compared with use of RTV-boosted IDV.116,117 
VI-D. Behavioral Intervention to Support Risk Reduction During nPEP Use  
Study findings from 2 randomized control trials underscore the importance of combining nPEP with behavioral 
interventions125 to support continuing risk reduction. In a randomized controlled counseling intervention trial 
among nPEP recipients at a single U.S. site, investigators compared behavioral effects among those who 
received 2 (standard) versus 5 (enhanced) risk-reduction counseling sessions. Both interventions were based on 
social cognitive theory, motivational interviewing, and coping effectiveness. Compared with baseline, a 
reduction occurred at 12 months in the reported number of condomless sex acts for both intervention arms. The 
group reporting ≤ 4 condomless sex acts during the previous 6 months at baseline benefitted more from the 2-
session intervention, while persons reporting ≥ 5 condomless sex acts during the previous 6 months at baseline 
revealed a greater reduction of condomless sex acts after receiving the 5-session intervention.126 These findings 
demonstrate that more counseling sessions might be necessary for persons reporting higher levels of sexual risk 
behavior when initiating nPEP. In another randomized control trial, MSM who received contingency 
management, a substance abuse intervention providing voucher-based incentives for stimulant-use abstinence, 
had greater nPEP completion rates, greater reductions in stimulant use, and fewer acts of condomless anal 
intercourse compared with control participants who received incentives that were not contingent on their 
substance abstinence.127  
VI-E. Adherence to nPEP Regimens and Follow-up Visits 
Difficulties in adherence have been noted in both maintaining adherence to daily doses of antiretroviral 
medication for 28 days among the majority of populations and adherence to follow-up clinical visits for HIV 
testing and other care. Such adherence difficulties appear particularly severe in studies of nPEP for sexually 
assaulted persons. Methods for measuring completion of nPEP medication regimen differed across studies, and 
loss to follow-up was a major hindrance to assessing medication adherence for the majority of studies.  
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In a systematic review and meta-analysis of 34 nPEP studies not including sexual assault and 26 nPEP studies 
including only sexual assault, nPEP completion rates were lowest among persons who experienced sexual 
assault (40.2% [95% CI = 31.2%, 49.2%]) and highest among persons who had other nonoccupational 
exposures (65.6% [95% CI = 55.6%, 75.6%]).128 In a separate meta-analysis of 24 nPEP-related studies, 
including 23 cohort studies and 1 randomized behavioral intervention to improve nPEP adherence, of 2,166 
sexually assaulted persons receiving nPEP and pooled across the 24 studies, 40.3% (95% CI = 32.5%–48.1%; 
range, 11.8%–73.9%) adhered to a 28-day course of nPEP, and 41.2% (95% CI = 31.1%–51.4%; range, 2.9%–
79.7%) did not return to pick up their prescribed medication or did not return for follow-up appointments.20 
Medication adherence was measured in 24 studies by using varying methodology, including pill count, volume 
of syrup remaining, self-report, counts of number of pharmacy visits, recall of number of doses taken by 
notation on a calendar, number of prescriptions filled, and number of weekly clinic appointments kept. Reported 
medication adherence was lower in developed countries (n=15 studies, 5 countries)23,30-32,36,38,46,50,58,88-92,94,97 
compared with developing countries (n=8 studies, three countries)40,42,85-87,93,95,96 (33.3% versus 53.2%, 
respectively; P=0.007), possibly due to higher awareness of HIV transmission risk in countries with a high HIV 
prevalence.20 Eight of the 24 (33%) studies30,32,46,86-89,97 provided nPEP medications at time of initiation of 
prophylaxis as starter packs including 4–7 days of medication, and 1 study provided either a starter pack of 
medications or a full 28-day supply of nPEP at initiation.96 In this latter study, the proportion who adhered to 
the 28 days of nPEP was 29% for patients initially receiving the starter pack and 71% for patients receiving a 
full 28-day supply.96 
Although sexually assaulted persons are sometimes at risk for HIV transmission, they often decline nPEP, and 
many who do take it do not complete the 28-day course. This pattern has been reported in multiple countries 
and in programs in North America. In Ontario, for example, 798 of 900 eligible sexually assaulted persons were 
offered nPEP, including 69 and 729 at high or unknown risk for HIV transmission due to the factors associated 
with their sexual assault, respectively.23 Forty-six (67%) of 69 persons at high risk for HIV transmission and 
301 (41%) of 729 persons with unknown risk accepted and initiated nPEP. Twenty-four percent of patients at 
high risk and 33% of patients with unknown risk completed the 28-day course. Reasons for discontinuing 
treatment were documented in 96 cases and included adverse effects (81%), interference with routine (42%), 
inability to take time away from work or school (22%), and reconsideration of HIV risk (19%). 
Of the observational studies of sexually assaulted persons provided nPEP, the majority identified similar 
challenges. Studies have demonstrated that early discontinuation of medication and a lack of follow-up pose 
challenges to providing nPEP to sexually assaulted persons.31,33,47,50 
Four international studies examined adherence among both men and women with non-assault sexual and 
injection drug use risk exposures.46,48,49,51 Full medication adherence in these studies ranged from 60%–88%; 
60%48 and 79%51 completed therapy (without specifying how completion was defined) and 67%48 and 88%49 
completed 28 days or 4 weeks of nPEP. The proportion of MSM who adhered to nPEP medication for 28 days 
reported in those studies ranged from 42%–91%. 
Studies that used a fixed dose combination of ZDV/3TC and LPV/r as primary components in the nPEP drug 
regimen reported low medication adherence for 28 days (24%–44%).23,44,47 A study among MSM compared use 
of a fixed-dose combination regimen containing TDF/FTC with or without RAL (an integrase inhibitor) with 
ZDV/3TC and a RTV-boosted PI; adherence rates were superior for the TDF-containing regimens (57% [with 
RAL]–72.7% [without RAL]) compared with the PI-containing regimen (46%). Although 57% of the 
TDF/FTC/RAL arm reported taking their medications as directed, an additional 27% took their once daily 
medication, but sometimes missed their second daily dose of RAL.57  
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VI-F. nPEP Cost-effectiveness 
Estimates of cost-effectiveness of nPEP as an HIV prevention method reported in the literature vary by HIV 
exposure route and estimated prevalence of infection among source persons. A study using data from the San 
Francisco nPEP program estimated the cost-effectiveness of hypothetical nPEP programs in each of the 96 
metropolitan statistical areas in the United States.129 It included 3 different data sources, including data from 
clinical care and drug cost data from the San Francisco Department of Public Health nPEP program,130 
estimates of the per-act probability of HIV transmission associated with different modes of sexual and 
parenteral HIV exposure,131-133 and HIV prevalence data from 96 U.S. metropolitan statistical areas.134 
Investigators estimated the cost-effectiveness of hypothetical nPEP programs as an HIV prevention method in 
each area compared with no intervention. By defining cost-effective programs as those costing 
<$60,000/quality-adjusted life year (QALY), that study found nPEP programs were cost-effective across the 
combined metropolitan statistical areas with a cost utility ratio of $12,567/QALY saved (range, $4,147–
$39,101). nPEP was most cost-effective for MSM ($4,907/QALY). It was not cost-effective for needle-sharing 
persons who inject drugs (PWID) ($97,867/QALY), persons sustaining nonoccupational needlesticks 
($159,687/QALY), and receptive female partners ($380,891/QALY) or insertive male partners 
($650,792/QALY) in penile-vaginal sex. The hypothetical nPEP program would be cost-saving (cost-utility 
ratio, <$0) only for men and women presenting with receptive anal intercourse or if nPEP use was limited to 
clients with known HIV-infected partners.129 In another study limited to San Francisco, the overall cost-utility 
ratio for the existing nPEP program was $14,449/QALY saved and for men experiencing receptive anal sex, the 
nPEP program was cost-saving.130  
Studies in Australia and France reported similar results. For example, in Australia, using a threshold for cost-
effectiveness of $50,000/QALY, nPEP was cost-effective among persons having CAI with an HIV-infected 
source ($40,673/QALY).135 In France, using thresholds for cost-saving and cost-effectiveness of €0/QALY 
saved and <€50,000/QALY saved, respectively, nPEP was cost-saving among men and women who had 
receptive anal intercourse with an HIV-infected man (-€22,141/QALY saved [men]; and -€22,031/QALY saved 
[women]) and cost-saving among PWID having shared needles with an HIV-infected person (-€1,141/QALY 
saved).136  
Additionally, these same French and Australian studies, and a Swiss study, reported that HIV testing to 
determine the status of the source person (when possible) was determined to reduce costs associated with nPEP 
programs by avoiding unnecessary prophylaxis.48,135,136  
VI-G. Attitudes, Policies, and Knowledge About nPEP Use Among Health Care Providers and 
Candidates for nPEP  
Since 1997, certain health care providers, health policy makers, and scientific investigators of nPEP have 
recommended wider availability and/or use of nPEP,24,131,137-144 while others have been more cautious about 
implementing it in the absence of definitive evidence of efficacy or effectiveness.145,146 Multiple public health 
jurisdictions in the U.S., including the New York State AIDS Institute, the San Francisco County Health 
Department, the Massachusetts Department of Public Health, the Rhode Island Department of Health, and the 
California State Office of AIDS, have issued policies or advisories for nPEP use.3,4,147,148 
Surveys of health care providers and facilities indicate a low level of awareness and capacity to provide nPEP as 
well as a lack of access for nPEP for those for whom it is recommended need for more widespread 
dissemination and implementation of guidelines and protocols for nPEP use and a need for improved access. In 
a study of 181 patients presenting to the emergency department (ED) who had been sexually assaulted, lack of 
insurance, older patient age, and acquaintance rape were factors associated with not being offered nPEP.30 A 
study evaluating access to nPEP services in 117 health care sites in Los Angeles County through use of Internet 
2016 nPEP Guidelines Update Page 22 of 91 
searches and telephone surveys, determined that only 14% offered nPEP to clients regardless of insurance 
status, and an even lower percentage, 8%, offered nPEP to uninsured clients, indicating the need to improve 
access to such services.149 A survey in New York State (NYS) reported that among 184 EDs, 88% reported 
evaluating patients with possible nonoccupational exposures to HIV in accordance with NYS guidelines, 
however, full implementation of NYS nPEP guidelines was incomplete with 4% neither supplying nor 
prescribing antiretroviral drugs in the ED and only 22% confirming whether linkage to follow-up care was 
successful.150 Screening of STIs, risk-reduction counseling, and education about symptoms of acute HIV 
seroconversion were not consistently performed according to the NYS guidelines.150 Additionally, in a survey 
of 142 HIV health care providers in Miami and the District of Columbia, prescribing nPEP was associated with 
having patients request nPEP, or having a written nPEP protocol, although most providers reported not having a 
written nPEP protocol and that patients rarely or never requested nPEP.151 Lack of prescribing nPEP was 
associated with believing that nPEP would lead to antiretroviral resistance.151 More health care providers in the 
District of Columbia compared with those in Miami, prescribed nPEP (59.7% versus 39.5%, respectively 
P < 0.048).152 In a cross-sectional study describing program practices related to HIV testing and nPEP among 
174 sexual assault nurse examiner (SANE)/forensic nurse examiner (FNE) programs in the U.S. and Canada, 
75% had nPEP policies, 31% provided HIV testing, and 63% offered nPEP routinely or based on patient 
request.153 Medication cost was the most important barrier to providing nPEP in these programs.  
Awareness, knowledge, and use of nPEP has been described among MSM.14,15,106,108,110,154 Evidence indicates 
awareness of nPEP and interest in its use among potential patients. When nPEP studies were established in San 
Francisco, approximately 400 persons sought treatment during December 1997–March 1999.106,154 In an HIV 
prevention trial of 4,295 MSM in 6 U.S. cities during 1999–2003, a total of 2,037 (47%) had heard of nPEP at 
baseline and 315 (7%) reported using nPEP on ≥1 occasion.14 Predictors of nPEP use included having multiple 
partners, engagement in condomless sex with a known HIV-infected partner or with a partner of unknown HIV 
status, and use of illicit drugs. Among 1,427 MSM in a community cohort of HIV-negative men in Sydney, 
Australia, during 2001–2007, knowledge of nPEP increased from 78.5% at baseline to 97.4% by the fifth annual 
interview, and nPEP use increased from 2.9/100 person-years in 2002 to 7.1/100 person-years in 2007.110 
During 2006–2009, knowledge of nPEP among MSM from urban areas in the Netherlands increased from 46% 
to 73%.108 Also, the annual number of PEP prescriptions to MSM in Amsterdam increased 3-fold, from 19 in 
2000 to 69 in 2007.15  
In a study of 227 pediatric and adolescent patients aged 9 months–18 years who were evaluated for sexual 
assault in Atlanta, Georgia, 40% of patients were examined ≤ 72 hours after the sexual assault, of whom 81% 
reported a history of genital or anal trauma.41 In that study, patients aged 13–18 years and those who reported 
sexual assault by a stranger were more likely to present to the ED ≤ 72 hours after the sexual assault. Health 
care providers in the hospital’s ED where this nPEP study was conducted expressed reluctance to prescribe 
nPEP to pre-pubertal children. For example, of 87 children and adolescents seen in the ED ≤ 72 hours after the 
assault, 23 had anogenital trauma or bleeding, and 5 were offered nPEP.  
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VII. PATIENT MANAGEMENT GUIDELINES  
VII-A. Initial Evaluation of Persons Seeking Care After Potential Nonoccupational Exposure to HIV  
Effective delivery of nPEP after exposures that carry a substantial risk for HIV infection requires prompt 
evaluation of patients and consideration of biomedical and behavioral interventions to address current and 
ongoing health risks. The initial evaluation provides the information necessary for determining if nPEP is 
indicated (Figure 1).  
Figure 1. Algorithm for evaluation and treatment of possible nonoccupational HIV exposures  
 
Procedures at the evaluation visit include determining the HIV infection status of the potentially exposed person 
and the source person (if available), the timing and characteristics of the exposure for which care is being 
sought, and the frequency of possible HIV exposures. Additionally, to determine whether other treatment or 
prophylaxis is indicated, health care providers should assess the likelihood of STIs, infections efficiently 
transmitted by injection practices or needlesticks (e.g., hepatitis B or hepatitis C virus), and pregnancy for 
women.  
VII-A1. HIV Status of the Potentially Exposed Person 
nPEP is only indicated for potentially exposed persons without HIV infection. Because potentially exposed 
persons might have acquired HIV infection already and be unaware of it, routine HIV antibody testing should 
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be performed on all persons seeking evaluation for potential nonoccupational HIV exposure. If possible, this 
should be done with an FDA-approved rapid antibody or Ag/Ab blood test kit with results available within an 
hour. If HIV blood test results will be unavailable during the initial evaluation visit, a decision whether nPEP is 
indicated should be made based on the initial assumption that the potentially exposed patient is not infected. If 
medication of HIV prophylaxis is indicated by the initial evaluation and started, it can be discontinued if the 
patient is later determined to already have HIV infection. 
VII-A2. Timing and Frequency of Exposure  
Available data from animal studies indicate that nPEP is most effective when initiated as soon as possible after 
HIV exposure; it is unlikely to be effective when instituted > 72 hours after exposure.83 Therefore, persons 
should seek nPEP as soon as possible after an exposure that might confer substantial risk and health care 
providers should evaluate such patients rapidly and initiate nPEP promptly when indicated.  
nPEP should be provided only for infrequent exposures. Persons who engage in behaviors that result in 
frequent, recurrent exposures that would require sequential or near-continuous courses of antiretroviral 
medications (e.g., HIV-discordant sex partners who inconsistently use condoms or PWID who often share 
injection equipment) should not be prescribed frequent, repeated courses of nPEP. Instead, health care providers 
should provide persons with repeated HIV exposure events (or coordinate referrals for) intensive sexual or 
injection risk-reduction interventions, and consider the prescription of daily oral doses of the fixed-dose 
combination of TDF and FTC (Truvada, Gilead Sciences, Inc., Foster City, California) for PrEP.11 However, if 
the most recent recurring exposure is within the 72 hours prior to an evaluation, nPEP may be indicated with 
transition of the patient to PrEP after completion of 28 days of nPEP medication. 
In the special case of children with evidence of chronic sexual abuse who come to the attention of a health care 
provider ≤ 72 hours after their most recent exposure, nPEP can be considered on a case-by-case basis. In 
addition, child protective services should be engaged for consideration of removal of the child from exposure to 
the perpetrator of the sexual abuse.  
VII-A3. HIV Acquisition Risk from the Exposure  
In addition to determining when the potential exposure occurred, determining whether nPEP is indicated 
requires assessing if the reported sexual, injection drug use, or other nonoccupational exposure presents a 
substantial risk for HIV acquisition. Health care providers should consider 3 main factors in making that 
determination: (1) whether the exposure source is known to have HIV infection, (2) to which potentially 
infected body fluid(s) the patient was exposed, and (3) the exposure site or surface.  
The highest level of risk is associated with exposure of susceptible tissues to potentially infected body fluid(s) 
from persons known to have HIV infection, particularly those who are not on antiretroviral treatment. Persons 
with exposures to potentially infectious fluids from persons of unknown HIV status are at unknown risk for 
acquiring HIV infection. When the source of exposure is known to be from a group with a high prevalence of 
HIV infection (e.g., a man who has sex with men or a PWID who shares needles or other injection equipment), 
the risk for unrecognized HIV infection in the source is increased.  
The estimated per-act transmission risk, when exposed to infectious fluid(s) from a person with HIV infection, 
varies considerably by exposure route (Table 1).155 The highest estimated per-act risks for HIV transmission are 
associated with blood transfusion, needle sharing during injection drug use, receptive anal intercourse, and 
percutaneous needlestick injuries. Insertive anal intercourse, insertive penile-vaginal intercourse, and oral sex 
represent substantially lower per-act transmission risk.  
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Table 1. Estimated per-act risk for acquiring human immunodeficiency virus (HIV) from an infected source, by 
exposure acta 
Exposure type 
Rate for HIV acquisition 
per 10,000 exposures 
Parenteral 
Blood transfusion 9,250 
Needle sharing during injection drug use 63 
Percutaneous (needlestick) 23 
Sexual 
Receptive anal intercourse 138 
Receptive penile-vaginal intercourse 8 
Insertive anal intercourse 11 
Insertive penile-vaginal intercourse 4 
Receptive oral intercourse Low 




Throwing body fluids (including semen or saliva) Negligible 
Sharing sex toys Negligible 
Source: http://www.cdc.gov/hiv/policies/law/risk.html 
a  Factors that may increase the risk of HIV transmission include sexually transmitted diseases, acute and late-stage 
HIV infection, and high viral load. Factors that may decrease the risk include condom use, male circumcision, 
antiretroviral treatment, and preexposure prophylaxis. None of these factors are accounted for in the estimates 
presented in the table. 
b  HIV transmission through these exposure routes is technically possible but unlikely and not well documented. 
 
A history should be taken of the specific sexual, injection drug use, or other exposure events that can lead to 
acquiring HIV infection. Eliciting a complete description of the exposure and information about the HIV status 
of the partner(s) can substantially lower (e.g., if the patient was exclusively the insertive partner or a condom 
was used) or increase (e.g., if the partner is known to be HIV-positive) the estimate of risk for HIV transmission 
resulting from a specific exposure.  
Percutaneous injuries from needles discarded in public settings (e.g., parks and buses) sometimes result in 
requests for nPEP. Although no HIV infections from such injuries have been documented, concern exists that 
syringes discarded by PWID might pose a substantial risk. However, such injuries typically involve small-bore 
needles that contain only limited amounts of blood, and the infectiousness of any virus present might be 
low.156,157 Saliva that is not contaminated with blood contains HIV in much lower titers and constitutes a 
negligible exposure risk,158 but saliva that is contaminated with HIV-infected blood poses a substantial exposure 
risk. HIV transmission by this route has been reported in ≥ 4 cases.159-162  
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VII-A4. HIV Status of the Exposure Source 
When the exposure source’s HIV status is unknown, that person’s availability for HIV testing should be 
determined. When the source person is available and consents to HIV testing, a clinical evaluation visit should 
be arranged that includes HIV testing by using a fourth-generation combined Ag/Ab test. The risk for 
transmission might be especially great if the source person has been infected recently because the viral burden 
in blood and semen might be particularly high.163,164 However, ascertaining this in the short time available for 
the initial nPEP evaluation might not be possible. If the risk associated with the exposure is high, starting nPEP 
and then making a decision whether to continue nPEP after the source’s HIV status is determined is 
recommended.  
If the exposure source is known to have HIV infection at the time of the nPEP evaluation visit and consents, the 
health care provider should attempt to interview that person or that source person’s health care provider to 
determine the history of antiretroviral use and most recent viral load. That information might help guide the 
choice of nPEP medications to avoid prescribing antiretroviral medications to which the source-virus is likely to 
be resistant. If the person with HIV infection is willing, the clinician might consider drawing blood for viral 
load and resistance testing, the results of which might be useful in modifying the initial nPEP medications if the 
results can be obtained promptly.165 
VII-B. Laboratory Testing 
Laboratory testing is required to (1) document the HIV infection status of the person presenting for nPEP 
evaluation (and the exposure source when available and consent has been granted), (2) identify and clinically 
manage any other conditions potentially resulting from sexual- or injection-related exposure to potentially 
infected body fluids, (3) identify any conditions that would affect the nPEP medication regimen, and 
(4) monitor for safety or toxicities related to the regimen prescribed (Table 2).  
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Table 2. Recommended schedule of laboratory evaluations of source and exposed persons for providing nPEP 












 For all persons considered for or prescribed nPEP for any exposure 
HIV Ag/Ab testinga 
(or antibody testing if Ag/Ab test 
unavailable)  
    b 
Hepatitis B serology, including: 
hepatitis B surface antigen  
hepatitis B surface antibody  
hepatitis B core antibody 
  — — c 
Hepatitis C antibody test   — — d 
  For all persons considered for or prescribed nPEP for sexual exposure 
Syphilis serologye    —  
Gonorrheaf   g — — 
Chlamydiaf   g — — 
Pregnancyh —   — — 
 For persons prescribed  
tenofovir DF+ emtricitabine + raltegravir  
or 
tenofovir DF+ emtricitabine + dolutegravir 
Serum creatinine  
(for calculating estimated creatinine clearancei)   — — 
Alanine transaminase, aspartate 
aminotranferase    — — 
 For all persons with HIV infection confirmed at any visit 
HIV viral load   j 
HIV genotypic resistance   j 
Abbreviations: Ag/Ab, antigen/antibody combination test; HIV, human immunodeficiency virus; nPEP, nonoccupational postexposure 
prophylaxis; tenofovir DF, tenofovir disoproxil fumarate. 
a  Any positive or indeterminate HIV antibody test should undergo confirmatory testing of HIV infection status. 
b  Only if hepatitis C infection was acquired during the original exposure; delayed HIV seroconversion has been seen in persons who 
simultaneously acquire HIV and hepatitis C infection. 
c  If exposed person susceptible to hepatitis B at baseline. 
d  If exposed person susceptible to hepatitis C at baseline. 
e  If determined to be infected with syphilis and treated, should undergo serologic syphilis testing 6 months after treatment 
f  Testing for chlamydia and gonorrhea should be performed using nucleic acid amplification tests. For patients diagnosed with a 
chlamydia or gonorrhea infection, retesting 3 months after treatment is recommended. 
• For men reporting insertive vaginal, anal, or oral sex, a urine specimen should be tested for chlamydia and gonorrhea.  
• For women reporting receptive vaginal sex, a vaginal (preferred) or endocervical swab or urine specimen should be tested for 
chlamydia and gonorrhea. 
• For men and women reporting receptive anal sex, a rectal swab specimen should be tested for chlamydia and gonorrhea.  
• For men and women reporting receptive oral sex, an oropharyngeal swab should be tested for gonorrhea. 
(http://www.cdc.gov/std/tg2015/tg-2015-print.pdf) 
g  If not provided presumptive treatment at baseline, or if symptomatic at follow-up visit. 
h  If woman of reproductive age, not using effective contraception, and with vaginal exposure to semen. 
i  eCrCl = estimated creatinine clearance calculated by the Cockcroft-Gault formula; eCrClCG = [(140 − age) x ideal body weight] ÷ 
(serum creatinine x 72) (x 0.85 for females). 
j  At first visit where determined to have HIV infection. 
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VII-B1. HIV Testing 
All patients initiating nPEP after potential HIV exposure should be tested for the presence of HIV-1 and HIV-2 
antigens and antibodies in a blood specimen at baseline (before nPEP initiation), preferably using a rapid test. 
Patients with baseline rapid tests indicating existing HIV infection should not be started on nPEP. Patients for 
whom baseline HIV rapid test results indicate no HIV infection or rapid HIV test results are not available 
should be offered nPEP. There should be no delay in initiation of nPEP while awaiting baseline HIV test results. 
Repeat HIV testing should occur at 4–6 weeks and 3 months after exposure to determine if HIV infection has 
occurred. See http://www.cdc.gov/hiv/testing/laboratorytests.html regarding information on approved HIV tests. 
Oral HIV tests are not recommended for use among persons being evaluated for nPEP. 
Additionally, persons whose sexual or injection-related exposures results in concurrent acquisition of HCV and 
HIV infection might have delayed HIV seroconversion. This has been documented among MSM with sexual 
exposure13 and health care personnel receiving oPEP for needlestick exposures.166,167 Therefore, for any person 
whose HCV antibody test is negative at baseline but positive at 4–6 weeks after the exposure, HIV antibody 
tests should be conducted at 3 and 6 months to rule out delayed seroconversion (see Table 2).  
VII-B2. Recognizing Acute HIV Infection at Time of HIV Seroconversion 
Persons initiating nPEP, if it fails, may experience signs and symptoms of acute HIV infection while on nPEP. 
At the initial visit, patients should be instructed about the signs and symptoms associated with acute (primary) 
HIV infection (Table 3), especially fever and rash,168 and asked to return for evaluation if these occur during the 
28 days of prophylaxis or anytime within a month after nPEP concludes. 
Table 3. Clinical signs and symptoms of acute (primary) human immunodeficiency virus infection169,170 
  Sex Mode of HIV acquisition 
Features  
Overall 
(n = 375), 
% 
Male 
(n = 355), 
% 
Female 
(n = 23), 
% 
Sexual 
(n = 324), 
% 
Injection drug use 
(n = 34), 
% 
Fever 75 74 83 77 50 
Fatigue 68 67 78 71 50 
Myalgia 49 50 26 52 29 
Skin rash 48 48 48 51 21 
Headache 45 45 44 47 30 
Pharyngitis 40 40 48 43 18 
Cervical adenopathy 39 39 39 41 27 
Arthralgia 30 30 26 28 26 
Night sweats 28 28 22 30 27 
Diarrhea 27 27 21 28 23 
 
Acute HIV infection is associated with high viral load. However, health care providers should be aware that 
available assays might yield low viral-load results (e.g., <3,000 copies/ml) among persons without HIV 
infection (i.e., false-positives). Without confirmatory tests, such false-positive results can lead to misdiagnoses 
of HIV infection.171 Transient, low-grade viremia has been observed among persons exposed to HIV who were 
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administered antiretroviral nPEP172 and did not become infected. In certain cases, this outcome might represent 
aborted infection rather than false-positive test results, but this can be determined only through further testing.  
All patients who have begun taking nPEP and for whom laboratory evidence later confirms acute HIV infection 
at baseline or whose follow-up antibody testing indicates HIV infection, should be transferred rapidly to the 
care of an HIV treatment specialist (if nPEP was provided by another type of health care provider). If the patient 
is taking a 3-drug antiretroviral regimen for nPEP at the time of HIV infection diagnosis, the 3-drug regimen 
should not be discontinued by the nPEP provider until the patient has been evaluated and a treatment plan 
initiated by an experienced HIV care provider.173  
VII-B3. STI Testing 
Any sexual exposure that presents a risk for HIV infection might also place a person at risk for acquiring other 
STIs.174 For all persons evaluated for nPEP because of exposure during sexual encounters, STI-specific nucleic 
acid amplification (NAAT) testing is recommended for gonorrhea and chlamydia,174 by testing first-catch urine 
or with swabs collected from each mucosal site exposed to potentially infected body fluids (oral, vaginal, 
cervical, urethral, rectal).174,175 Additionally, blood tests for syphilis should be conducted for all persons 
evaluated for nPEP. 
VII-B4. HBV Testing 
HBV infection is of specific concern when considering nPEP for 2 reasons. First, multiple medications used for 
nPEP, including 2 in the preferred regimen (TDF and FTC) are active against HBV infection. For safety 
reasons, health care providers need to know if a patient has active HBV infection (positive hepatitis B surface 
antigen [HBsAg]) so that the patient can be closely monitored for reactivation “flare ups” when nPEP is 
stopped, and treatment for HBV infection is discontinued. Although this is rare, it can result in substantial 
hepatic dysfunction if not detected and treated early. Additionally, obtaining hepatitis serology (HBsAg, 
hepatitis B surface antibody [anti-HBs], and hepatitis B core antibody [anti-HBc]) will identify nonimmune 
persons who should be provided hepatitis B vaccination Table 4).176 
Table 4. Hepatitis B virus screening serology177  
HBsAg Anti-HBc Anti-HBs 
IgM  
Anti-HBc Interpretation Action 
Negative Negative Negative — Susceptible Vaccinate 
Negative Positive Positive — Immune (natural infection) Document 
Negative Negative Positive — Immune (prior vaccination) Document 
Positive Positive Negative Negative Chronic hepatitis B virus infection Evaluate for treatment 
Positive Positive Negative Positive Acute hepatitis B virus infection Follow and evaluate 
for treatment 
Negative Positive Negative — Unclear—might be: 
• resolved infection (most common) 
• false-positive anti-HBc; susceptible 
• “low level” chronic infection 
• resolving acute infection 
Case-by-case 
evaluation 
Abbreviations: HBsAg, hepatitis B surface antigen; anti-HBc, hepatitis B core antibody; anti-HBs, hepatitis B surface antibody.  
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VII-B5. Pregnancy Testing 
nPEP is not contraindicated for pregnant women. Moreover, because pregnancy has been demonstrated to 
increase susceptibility to sexual HIV acquisition,178 nPEP can be especially important for women who are 
pregnant at the time of sexual HIV exposure.  
For women of reproductive capacity who have had genital exposure to semen and a negative pregnancy test 
when evaluated for possible nPEP, current contraception use should be assessed, and if a risk for pregnancy 
exists, emergency contraception should be discussed with the patient.  
VII-B6. Baseline and Follow-up Testing to Assess Safety of Antiretroviral Use for nPEP 
All patients who will be prescribed nPEP should have serum creatinine measured and an estimated creatinine 
clearance calculated at baseline to guide selection of a safe and appropriate antiretroviral regimen for nPEP. 
Also, health care providers treating patients with nPEP should monitor liver function, renal function, and 
hematologic parameters when indicated by the prescribing information for the antiretrovirals prescribed. Drug-
specific recommendations are available at the online AIDSInfo Drugs Database at: http://aidsinfo.nih.gov/drugs 
or the antiretroviral treatment guidelines.114,173,179  
Unusual or severe toxicities from antiretroviral drugs should be reported to the manufacturer or FDA 
(http://www.accessdata.fda.gov/scripts/medwatch/medwatch-online.htm, or 1-800-FDA-1088 [1-800-332-
1088]).  
If nPEP is prescribed to a woman who is pregnant at the time of exposure or becomes pregnant while on nPEP, 
health care providers should enter the patient’s information (anonymously) into the Antiretroviral Pregnancy 
Registry (http://www.apregistry.com). 
VII-C. Recommended Antiretroviral nPEP Regimens 
A 28-day course of nPEP is recommended for HIV-uninfected persons who seek care ≤ 72 hours after a 
nonoccupational exposure to blood, genital secretions, or other potentially infected body fluids of persons 
known to be HIV infected or of unknown HIV status when that exposure represents a substantial risk for HIV 
acquisition. Since adherence is critical for nPEP efficacy, it is preferable to select regimens that minimize side 
effects, number of doses per day and the number of pills per dose. 
No strong evidence exists, based on randomized clinical trials, that any specific combination of antiretroviral 
medication is optimal for nPEP use. Although a limited number of studies have evaluated the penetration of 
antiretroviral medications into genital tract secretions and tissues,180-182 evidence is insufficient for 
recommending a specific antiretroviral medication as most effective for nPEP for sexual exposures. Therefore, 
the recommended regimens for nPEP in these guidelines are based on expert opinion from the accumulated 
experience with antiretroviral combinations that effectively suppress viral replication among HIV-infected 
persons for the purpose of HIV treatment and mainly observational studies of the medication tolerance and 
adherence when these same drugs are taken for nPEP. 
The recommendation for a 3-drug antiretroviral regimen is based on extrapolation of data demonstrating that the 
maximal suppression of viral replication occurs among persons with HIV infection when combination 
antiretroviral therapy with ≥3 drugs is provided. Also, the likelihood of protection against acquiring resistant 
virus would be greater with a 3-drug regimen compared with a 2-drug regimen. Recommending a 3-drug 
regimen for all patients who receive nPEP will increase the likelihood of successful prophylaxis in light of 
potential exposure to virus with resistance mutation(s) and will provide consistency across PEP guidelines for 
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both nPEP and oPEP.2 Additionally, if infection occurs despite nPEP, a 3-drug regimen will more likely limit 
emergence of resistance than a 2-drug regimen.  




Adults and adolescents aged ≥ 13 
years, including pregnant women, with 
normal renal function (creatinine 
clearance ≥ 60 mL/min) 
Preferred 
A 3-drug regimen consisting of 
tenofovir DF 300 mg and fixed dose combination 
emtricitabine 200 mg (Truvadac) once daily 
  with 
raltegravir 400 mg twice daily 
  or 
dolutegravir 50 mg once daily 
Alternative 
A 3-drug regimen consisting of 
tenofovir DF 300 mg and fixed dose combination 
emtricitabine 200 mg (Truvada) once daily 
  with 
darunavir 800 mg (as 2, 400-mg tablets) once daily 
  and 
ritonavirb 100 mg once daily 
Adults and adolescents aged ≥ 13 years 
with renal dysfunction (creatinine 
clearance ≤59 mL/min) 
Preferred 
A 3-drug regimen consisting of 
zidovudine and lamivudine, with both doses adjusted to 
degree of renal function 
  with 
raltegravir 400 mg twice daily 
  or 
dolutegravir 50 mg once daily 
Alternative 
A 3-drug regimen consisting of 
zidovudine and lamivudine, with both doses adjusted to 
degree of renal function 
  with 
darunavir 800 mg (as 2, 400-mg tablets) once daily 
  and 
ritonavirb 100 mg once daily 
Children aged 2–12 years 
Preferred 
A 3-drug regimen consisting of 
tenofovir DF, emtricitabine, and raltegravir, 
with each drug dosed to age and weightd 
Alternative 
A 3-drug regimen consisting of 
zidovudine and lamivudine 
  with 
raltegravir 
  or 
lopinavir/ritonavirb, 
with raltegravir and lopinavir/ritonavir dosed to age and 
weightd 
Alternative 
A 3-drug regimen consisting of 
tenofovir DF and emtricitabine and lopinavir/ritonavirb,  
with each drug dosed to age and weightd 




Children aged 3–12 years Alternative 
A 3-drug regimen consisting of 
tenofovir DF and emtricitabine and darunavire/ritonavirb, 
with each drug dosed to age and weightd 
Children aged 4 weeksf–< 2 years Preferred 
A 3-drug regimen consisting of 
zidovudine oral solution and lamivudine oral solution 
  with 
raltegravir 
  or 
lopinavir/ritonavirb oral solution (Kaletrag), 
with each drug dosed to age and weightd 
Children aged 4 weeksf–< 2 years Alternative 
A 3-drug regimen consisting of 
zidovudine oral solution and emtricitabine oral solution 
  with 
raltegravir 
  or 
lopinavir/ritonavirb oral solution (Kaletra),  
with each drug adjusted to age and weightd 
Children aged birth–27 days Consult a pediatric HIV-specialist 
Abbreviations: HIV, human immunodeficiency virus; nPEP, nonoccupational postexposure prophylaxis; tenofovir DF, tenofovir 
disoproxil fumarate. 
a  These recommendations do not reflect current Food and Drug Administration-approved labeling for antiretroviral medications listed 
in this table. 
b  Ritonavir is used in clinical practice as a pharmacokinetic enhancer to increase the trough concentration and prolong the half-life of 
darunavir, lopinavir, and other protease inhibitors. Ritonavir is not counted as a drug directly active against HIV in the above “3-
drug” regimens. 
c Gilead Sciences, Inc., Foster City, California. 
d See also Table 6. 
e Darunavir only FDA-approved for use among children aged ≥ 3 years. 
f Children should have attained a postnatal age of ≥ 28 days and a postmenstrual age (i.e., first day of the mother’s last menstrual 
period to birth plus the time elapsed after birth) of ≥ 42 weeks. 
g AbbVie, Inc., North Chicago, Illinois. 
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Table 6. Formulations, cautions, and dose adjustments for antiretroviral medications in preferred and alternative nPEP regimensa 
Drug Formulation Side effects, contraindications, and cautions Dose adjustments 
Tenofovir disoproxil fumarate 
(TDF) 
(Viread, Gilead Sciences, Inc., 
Foster City, California) 
Also available as component of 
fixed-dose combination, Truvada  
(Gilead Sciences, Inc., Foster 
City, California)  






Side effects: Asthenia, headache, diarrhea, nausea, vomiting 
Contraindications: Nephrotoxicity; for nPEP, should not be 
administered to persons with acute or chronic kidney injury or 
those with eCrCl < 60 mL/min  
Cautions: TDF can be used in nPEP regimens for patients with 
chronic hepatitis B infection, but hepatic function tests should be 
closely monitored when regimen is stopped because withdrawal 
of this drug may cause an acute hepatitis exacerbation. 
Children aged 2–11 years (powder) 
• 8 mg/kg body weight 
• Not to exceed adult dose (300 mg qd) 
Children aged 2–11 years (tablet), per body weight 
• 17 to < 22 kg, 150 mg-tablet once daily 
• 22 to < 28 kg, 200 mg-tablet once daily 
• 28 to < 35 kg, 250-mg tablet once daily 
• ≥ 35 kg, 300-mg tablet once daily 
• Not to exceed adult dose (300 mg once daily) 
Emtricitabine (FTC) 
(Emtriva, Gilead Sciences, Inc., 
Foster City, California) 
Also available as component of 
fixed-dose combination, 
Truvada (FTC + TDF) 
200-mg capsule 
10-mg/mL oral solution 
Side effects: Hyperpigmented rash or skin discoloration 
Cautions: FTC can be used in nPEP regimens for patients with 
chronic hepatitis B infection, but hepatic function tests should be 
closely monitored when regimen is stopped because withdrawal 
of this drug might cause an acute hepatitis exacerbation. 
Contraindications: Do not administer with lamivudine 
Children aged 0–3 months (oral solution) 
• 3 mg/kg once daily  
• Not to exceed 240 mg once daily 
Children aged 3 months–17 years, per body weight  
• 6 mg/kg once daily (oral solution) 
• ≥ 33 kg 200-mg tablet once daily 
• Not to exceed 240 mg once daily 
Raltegravir (RAL) 
(Isentress, Merck & Co., Inc., 
Kenilworth, New Jersey) 
400-mg tablet 
100-mg chewable, scored 
tablet 
25-mg chewable tablet 
Side effects: Insomnia, nausea, fatigue, headache; severe skin 
and hypersensitivity reactions have been reported 
Cautions: Dosage adjustment required if co-administered with 
rifampin (800 mg twice daily for adults). Co-administration with 
antacids, laxatives, or other products containing polyvalent 
cations (Mg, Al, Fe, Ca, Zn), including iron, calcium, or 
magnesium supplements; sucralfate; buffered medications; and 
certain oral multivitamins can reduce absorption of RAL. RAL 
should be administered ≥ 2 hours before or ≥ 6 hours after 
administration of cation-containing medications or products, 
however, RAL can be co-administered with calcium carbonate-
containing antacids.154 
Contraindications: None 
Children aged 6–12 years and weighing > 25 kg  
• 400 mg-tablet twice daily 
Or 
• Chewable tablets twice daily. See table below for 
chewable tablet dose. 
Children aged 2–12 years (chewable tablets), per 
body weight 
• 11 to < 14 kg, 75-mg twice daily  
• 14 to < 20 kg, 100-mg twice daily 
• 20 to < 28 kg, 150-mg twice daily 
• 28 to < 40 kg, 200-mg twice daily 
• ≥ 40 kg, 300-mg twice daily  
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Drug Formulation Side effects, contraindications, and cautions Dose adjustments 
Dolutegravir (DTG) 
(Tivicay, ViiV Healthcare, 
Brentford, Middlesex, United 
Kingdom) 
50-mg tablet Side effects: Insomnia, headache 
Cautions: Dosage adjustment required if co-administered with 
rifampin, fosmamprenavir/ritonavir, tipranvir/ritonavir, or efavirenz 
(50 mg twice daily for adults). Co-administration with antacids, 
laxatives, or other products containing polyvalent cations (Mg, Al, 
Fe, Ca, Zn), including iron, calcium, or magnesium supplements; 
sucralfate; buffered medications; and some oral multivitamins 
can reduce absorption of DTG. DTG should be administered ≥ 2 
hours before or at ≥ 6 hours after administration of cation-
containing medications or products.151 
Contraindications: Do not administer with dofetilide. 
Children aged 12 years old and older and weighing 
≥ 40 kg  
• 50-mg tablet once daily 
Darunavir (DRV)/ritonavir(RTV) 
(Prezista, Janssen Therapeutics, 







Side effects: Rash (sulfonamide allergy), diarrhea, nausea, 
headache 
Cautions: Must be administered with food; must be co-
administered with ritonavir; can cause hepatotoxicity. Use with 
caution with persons with known allergy to sulfonamide 
medications 
Contraindications: Co-administration of ritonavir with certain 
sedative hypnotics, antiarrhythmics, sildenafil, or ergot alkaloid 
preparations is contraindicated and might result in potentially life-
threatening adverse events. 
Children aged 3 to < 18 years and weight > 10 kg 
WEIGHT (KG)  DOSE (TWICE DAILY WITH FOOD)  
10 to < 11 kg* darunavir 200 mg (2.0 mL) plus ritonavir 
32 mg (0.4 mL†) 
11 to < 12 kg* darunavir 220 mg (2.2 mL) plus ritonavir 
32 mg (0.4 mL†) 
12 to < 13 kg* darunavir 240 mg (2.4 mL) plus ritonavir 
40 mg (0.5 mL†) 
13 to < 14 kg* darunavir 260 mg (2.6 mL) plus ritonavir 
40 mg (0.5 mL†) 
14 to < 15 kg* darunavir 280 mg (2.8 mL) plus ritonavir 
48 mg (0.6 mL†) 
15 to < 30 kg darunavir 375 mg (combination of tablets 
or 3.8 mL‡) plus ritonavir 48 mg (0.6 mL†) 
30 to < 40 kg darunavir 450 mg (combination of tablets 
or 4.6 mL‡) plus ritonavir 100 mg (tablet 
or 1.25 mL†)  
≥ 40 kg darunavir 600 mg (tablet or 6 mL) plus 
ritonavir 100 mg (tablet or 1.25 mL†) 
* The dose in children weighing 10–15 kg is 20 mg/kg 
darunavir and 3 mg/kg ritonavir per kg body weight per 
dose, which is higher than the weight-adjusted dose in 
children with higher weight. 
† Ritonavir 80 g/mL oral solution 
‡ The 375-mg and 450-mg darunavir doses are rounded for 
suspension-dose convenience. 
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Drug Formulation Side effects, contraindications, and cautions Dose adjustments 
Lopinavir (LPV)/ritonavir (RTV)  
(Kaletra, AbbVie Inc., North 
Chicago, Illinois) 
200/50-mg tablets  
100/25-mg tablets 
80/20-mg/mL oral solution 
Side effects: Nausea, vomiting, diarrhea 
Cautions: PR and QT interval prolongation have been reported. 
Use with caution with patients at risk for cardiac conduction 
abnormalities or receiving other drugs with similar effect. 
Do not administer to neonates before a postmenstrual age (first 
day of the mother’s last menstrual period to birth plus the time 
elapsed after birth) of ≥ 42 weeks and a postnatal age of ≥ 14 
days. 
Contraindications: Co-administration of ritonavir with certain 
sedative hypnotics, antiarrhythmics, sildenafil, or ergot alkaloid 
preparations is contraindicated and might result in potentially life-
threatening adverse events. 
Children aged 14 days–12 months, per body weight 
Suspension (lopinavir/ritonavir) 
• 16/4 mg/kg or 300/75 mg/m2 twice daily 
Children aged > 12 months–18 years, per body weight 
Suspension (lopinavir/ritonavir) 
• < 15 kg, 12/3 mg/kg twice daily 
• ≥ 15 kg to 40 kg, 10/2.5 mg/kg twice daily 
• > 40 kg, 400/100 mg twice daily 
• not to exceed the recommended adult dose (400/100 mg 
[5 mL] twice daily 
Children aged > 12 months–18 years 
Tablet, weight-based dosing (lopinavir/ritonavir) 
• 15 to 25 kg, 2 100/25-mg tablets twice daily 
• > 25 to 35 kg, 3 100/25-mg tablets twice daily 
• > 35 kg, 4 100/25-mg tablets twice daily or 2 200/50-mg 
tablets twice daily 
Ritonavirb(RTV) 
(Norvir, AbbVie, Inc., North 
Chicago, Illinois) 
100-mg tablets 
100-mg soft gelatin 
capsules 
80-mg/mL oral solution 
Side effects: Abdominal pain, asthenia, headache, malaise, 
anorexia, diarrhea, dyspepsia, nausea, vomiting, circumoral 
paresthesia, peripheral paresthesia, dizziness, and taste 
perversion. 
Cautions: PR and QT interval prolongation have been reported. 
Use with caution with patients at risk for cardiac conduction 
abnormalities or receiving other drugs with similar effect. Can 
cause hepatotoxicity, pancreatitis, or hyperglycemia 
Contraindications: Co-administration of ritonavir with certain 
sedative hypnotics, antiarrhythmics, sildenafil, or ergot alkaloid 
preparations is contraindicated and might result in potentially life-
threatening adverse events. 
• See pediatric dosage for use as a boosting agent with 
darunavir or lopinavir in respective darunavir and lopinavir 
sections of this table. 
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Drug Formulation Side effects, contraindications, and cautions Dose adjustments 
Zidovudine (ZDV; AZT) 
(Retrovir, ViiV Healthcare, 
Brentford, Middlesex, United 
Kingdom) 
100-mg capsule  
300-mg tablet 
10-mg/mL oral syrup 
10-mg/mL intravenous 
infusion 
Side effects: Nausea, vomiting, headache, insomnia, and 
fatigue 
Cautions: Can cause anemia and neutropenia 
Infants aged birth–41 days 
Full term (aged ≥ 35 weeks gestation at birth), per body 
weight 
Syrup 
• 4 mg/kg orally twice daily  
Intravenousc  
• 3.0 mg/kg, infused over 30 minutes, every 12 hours 
Premature (aged ≥ 30 to 35 weeks gestation at birth; 
from birth through day 14 of life; switch to full term 
infant dose at 15 days of life), per body weight 
Syrup 
• 2 mg/kg orally twice daily  
Intravenousc 
• 1.5 mg/kg, infused over 30 minutes, every 12 hours 
Premature (aged < 30 weeks gestation at birth; day 14–28 
of life; switch to full term infant dose at 29 days* of 
life), per body weight 
Syrup 
• 2 mg/kg orally twice daily  
Intravenousc  
• 1.5 mg/kg, infused over 30 minutes, every 12 hours  
Infants and children aged ≥35 weeks post-conception 
and at least 4 weeks post-delivery, per body weight 
Syrup or Capsules 
• 4 to < 9 kg, 12 mg/kg twice daily 
• 9 to < 30 kg, 9 mg/kg twice daily 
Tablet 
• ≥ 30 kg, 300-mg tablet twice daily 
* Note: Premature infants exposed to HIV after day 1 of life 
are switched to full-term infant dose at 29 days of life. 
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Drug Formulation Side effects, contraindications, and cautions Dose adjustments 
Lamivudine (3TC) 
(Epivir, ViiV Healthcare, 
Brentford Middlesex, United 
Kingdom) 
150-mg scored tablet 
100-mg tablet 
300-mg tablet 
10-mg/mL oral solution 
Side effects: Headache, nausea, malaise and fatigue, nasal 
signs and symptoms, diarrhea, and cough  
Cautions: 3TC may be used in nPEP regimens for patients with 
chronic hepatitis B infection, but hepatic function tests should be 
closely monitored when regimen is stopped since withdrawal of 
this drug may cause an acute hepatitis exacerbation. 
Contraindications: Do not administer with emtricitabine 
Neonates and infants, aged ≤ 27 days 
Oral solution 
• 2 mg/kg twice daily 
Children, aged ≥ 4 weeks 
Oral solution 
• 4 mg/kg (maximum dose 150 mg) twice daily 
Children aged < 16 years and weighing ≥ 14 kg  
Scored 150-mg tablet 
• 14 to < 20 kg, 75 mg (1/2 tablet) AM  
+ 75 mg (1/2 tablet) PM 
• 20 to < 25 kg, 75 mg (1/2 tablet) AM  
+ 150 mg (1 tablet) PM 
• ≥ 25 kg, 150 mg tablet twice daily 
Adolescents (aged ≥ 16 years) and adults, per 
body weight  
• < 50 kg, 4 mg/kg (up to 150 mg) twice daily 
• ≥ 50 kg, 150 mg twice daily or 300 mg once daily 
Abbreviations: eCrCl = estimated creatinine clearance calculated by the Cockcroft-Gault formula; eCrClCG = [(140 − age) x ideal body weight] ÷ (serum creatinine x 72) (x 0.85 for females); nPEP, 
nonoccupational postexposure prophylaxis. 
a  For most current dosing regimens for treatment naïve children, see 1) AIDSInfo Drugs Database at http://aidsinfo.nih.gov/drugs, 2) Drugs@FDA (FDA approved drug products index) at 
http://www.accessdata.fda.gov/scripts/cder/drugsatfda/, 3) Pediatric ARV treatment guidelines at http://aidsinfo.nih.gov/guidelines/html/2/pediatric-treatment-guidelines/0#, and 4) Perinatal 
guidelines at http://aidsinfo.nih.gov/guidelines/html/3/perinatal-guidelines/0 
b  Ritonavir is used in clinical practice as a pharmacokinetic enhancer to increase the trough concentration and prolong the half-life of darunavir, lopinavir, and other protease inhibitors 
c  Infants unable to receive oral dosing may receive intravenous dosing 
 
 
2016 nPEP Guidelines Update Page 38 of 91 
Health care providers might consider using antiretroviral regimens for nPEP other than those listed as preferred 
or alternative because of patient-specific information (e.g., an HIV-infected exposure source with known drug-
resistance or contraindications to ≥1of the antiretrovirals in a preferred regimen). In those cases, health care 
providers are encouraged to seek consultation with other health care providers knowledgeable in using 
antiretroviral medications for similar patients (e.g., children, pregnant women, those with comorbid conditions) 
(Appendix 4).  
Providers should be aware that abacavir sulfate (Ziagen, ViiV Healthcare, Brentford, Middlesex, United 
Kingdom) should not be prescribed in any nPEP regimen. Prompt initiation of nPEP does not allow time 
for determining if a patient has the HLA-B*5701 allele, the presence of which is strongly associated with 
a hypersensitivity syndrome that can be fatal.183  
Health care providers and patients who are concerned about potential adherence and toxicity or the additional 
cost associated with a 3-drug antiretroviral regimen might consider using a 2-drug regimen (i.e., a combination 
of 2 NRTIs or a combination of a PI and a NNRTI). However, this DHHS guideline recommends a 3-drug 
regimen in all cases when nPEP is indicated.  
VII-D. Prophylaxis for STIs and Hepatitis 
All adults and adolescents with exposures by sexual assault should be provided with prophylaxis routinely for 
STIs and HBV,174 as follows: 
• For gonorrhea, (male and female adults and adolescents),  
o ceftriaxone 250 mg intermuscular, single dose; 
o plus azithromycin, 1 g, orally, single dose; 
• For chlamydia (male and female adults and adolescents),  
o  azithromycin, 1 g, orally, single dose 
o or doxycycline, 100 mg, orally, twice a day for 7 days. 
• For trichomonas (female adults and adolescents), 
o metronidazole, 2 g, orally, single dose  
o or tinidazole, 2 g, orally, single dose 
All persons not known to be previously vaccinated against HBV, should receive hepatitis B vaccination 
(without hepatitis B immune globulin),174 with the first dose administered during the initial examination. If the 
exposure source is available for testing and is HBsAg-positive, unvaccinated nPEP patients should receive 
both hepatitis B vaccine and hepatitis B immune globulin during the initial evaluation. Follow-up vaccine 
doses should be administered during 1–2 months and at 4–6 months after the first nPEP dose. Previously 
vaccinated sexually assaulted persons who did not receive postvaccination testing should receive a single 
vaccine booster dose.  
HPV vaccination is recommended for female survivors aged 9–26 years and male survivors aged 9–21 years. 
For MSM with who have not received HPV vaccine or who have been incompletely vaccinated, vaccine can be 
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administered through age 26 years. The vaccine should be administered to sexual assault survivors at the time of 
the initial examination, and follow-up dose administered at 1–2 months and 6 months after the first dose.174 
Routine use of STI prophylaxis is not recommended for sexually abused or assaulted children.174  
VII-E. Considerations for All Patients Treated with Antiretroviral nPEP  
The patient prescribed nPEP should be counseled regarding potential associated side effects and adverse events 
specific to the regimen prescribed. Any side effects or adverse events requiring immediate medical attention 
should be emphasized.  
VII-E1. Provision of nPEP Starter Packs or a 28-day Supply at Initiation 
Patients might be under considerable emotional stress when seeking care after a potential HIV exposure and 
might not be attentive to, or remember, all the information presented to them before making a decision 
regarding nPEP. Health care providers should consider giving an initial prescription for 3–7 days of medication 
(i.e., a starter pack) or an entire 28-day course and scheduling an early follow-up visit. Provision of the entire 
28-day nPEP medication supply at the initial visit rather than a starter pack of 3–7 days has been reported to 
increase likelihood of adherence, especially when patients find returning for multiple follow-up visits 
difficult.96,184 Routinely providing starter packs or the entire 28-day course requires that health care providers 
stock nPEP drugs in their practice setting or have an established agreement with a pharmacy to stock, package 
and urgently dispense nPEP drugs with required administration instructions. At the patient’s second visit, health 
care providers can discuss the results of baseline HIV blood testing (if rapid tests were not used), provide 
additional counseling and support, assess medication side effects and adherence, or provide an altered nPEP 
medication regimen if indicated by side effects or laboratory test results. nPEP starter packs or 28-day supplies 
might also include such medications as antiemetics to alleviate recognized side effects of the specific 
medications prescribed, if they occur. Health care providers should counsel patients regarding which side 
effects might occur (Table 6), how to manage them, and when to contact the provider if they do not resolve.173  
VII-E2. Expert Consultation 
When health care providers are inexperienced with prescribing or managing patients on antiretroviral 
medications or when information from persons who were the exposure source indicates the possibility of 
antiretroviral resistance, consultation with infectious disease or other HIV-care specialists, if available 
immediately, is warranted before prescribing nPEP to determine the correct regimen. Similarly, consulting with 
specialists with experience using antiretroviral drugs is advisable when considering prescribing nPEP for certain 
persons—pregnant women (infectious disease specialist or obstetrician), children (pediatrician), or persons with 
renal dysfunction (infectious disease specialist or nephrologist). However, if such consultation is not available 
immediately, nPEP should be initiated promptly and, if necessary, revised after consultation is obtained. Expert 
consultation can be obtained by calling the PEPline at the National Clinician’s Consultation Center at 888-448-
4911 (additional information is available at http://nccc.ucsf.edu/clinician-consultation/pep-post-exposure-
prophylaxis/). 
VII-E3. Facilitating Adherence  
Observational studies have reported that adherence to nPEP regimens is often inadequate and has been 
especially so among sexual assault survivors. Medication adherence can be facilitated by (1) prescribing 
medications with fewer side effects, fewer doses per day, and fewer pills per dose; (2) educating the patient 
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regarding potential side effects of the specific medications prescribed and providing medications to assist if side 
effects occur (e.g., antiemetics); (3) recommending medication adherence aids (e.g., pill boxes); (4) helping 
patients incorporate doses into their daily schedules; and (5) providing a flexible and proactive means for 
patient–health care provider contact during the nPEP period.185,186 Also, establishing a trusting relationship and 
maintaining good communication about adherence can help to improve completion of the nPEP course. 
Adherence to the nPEP medications prescribed to children will depend on the involvement of and support 
provided to parents and guardians. 
VII-E4. HIV Prevention Counseling  
The majority of persons who seek care after a possible HIV exposure do so because of failure to initiate or 
maintain effective risk-reduction behaviors. Notable exceptions are sexual assault survivors and persons with 
community-acquired needlestick injuries.  
Although nPEP can reduce the risk for HIV infection, it is not always effective. Therefore, patients should 
practice protective behaviors with sex partners (e.g., consistent condom use) or drug-use partners (e.g., 
avoidance of shared injection equipment) throughout the nPEP course to avoid transmission to others if they 
become infected and after nPEP to avoid future HIV exposures.  
At follow-up visits, when indicated, health care providers should assess their patients’ needs for behavioral 
intervention, education, and services. This assessment should include frank, nonjudgmental questions about 
sexual behaviors, alcohol use, and illicit drug use. Health care providers should help patients identify ongoing 
risk concerns and develop plans for improving their use of protective behaviors.187  
To help patients obtain indicated interventions and services, health care providers should be aware of local 
resources for high-quality HIV education and ongoing behavioral risk reduction, counseling and support, 
inpatient and outpatient alcohol and drug-treatment services, family and mental health counseling services, and 
support programs for HIV-infected persons. Information regarding publicly funded HIV prevention programs 
can be obtained from state or local health departments.  
VII-E5. Providing PrEP After nPEP Course Completion 
Persons who engage in behaviors that result in frequent, recurrent exposures that would require sequential or 
near-continuous courses of nPEP should be offered PrEP11 at the conclusion of their 28-day nPEP medication 
course. Because no evidence exists that prophylactic antiretroviral use delays seroconversion and nPEP is 
highly effective when taken as prescribed, a gap is unnecessary between ending nPEP and beginning PrEP. 
Upon documenting HIV-negative status, preferably by using an Ag/Ab test, daily use of the fixed dose 
combination of TDF (300mg) and FTC (200 mg) can begin immediately for patients for whom PrEP is 
indicated. Clinicians with questions about prescribing PrEP, are encouraged to call the PrEPline 855-448-7737 
at the National Clinician Consultation Center or go to their website (http://nccc.ucsf.edu/clinician-
consultation/prep-pre-exposure-prophylaxis/). 
VII.E6. Providing nPEP in the Context of PrEP 
Patients fully adhering to a daily PrEP regimen as recommended by their health care practitioner are not in need 
of nPEP if they experience a potential HIV exposure while on PrEP. PrEP is highly effective when taken daily 
or near daily.11,188 For patients who report that they take their PrEP medication sporadically and those who did 
not take it within the week before the recent exposure, initiating a 28-day course of nPEP might be indicated. In 
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that instance, all nPEP baseline and follow-up laboratory evaluations should be conducted. After the 28-day 
nPEP regimen is completed, if confirmed to be HIV uninfected, the daily PrEP regimen can be reinitiated.  
VII-E7. Management of Source Persons with HIV Infection  
When persons who were the exposure source are present during the course of evaluating a patient for potential 
HIV exposure, health care providers should also assess that person’s access to relevant medical care, behavioral 
intervention, and social support services. If needed care cannot be provided directly, health care providers 
should help HIV-infected source persons obtain care in the community (http://locator.aids.gov/). 
VII-F. Additional Considerations 
VII-F1. Reporting and Confidentiality  
As with all clinical care, health care providers should handle nPEP evaluations with confidentiality. 
Confidential reporting of STIs and newly diagnosed HIV infections to health departments should occur as 
indicated by that jurisdiction’s local laws and regulations.  
For cases of sexual assault, health care providers should document their findings and assist patients with 
notifying local authorities.174 How health care providers should document and report their findings is beyond 
the scope of these guidelines. Laws in all 50 states strictly limit the evidentiary use of a survivor’s previous 
sexual history, including evidence of previously acquired STIs, to avoid efforts to undermine the credibility of 
the survivor’s testimony. Evidentiary privilege against revealing any aspect of the survivor’s examination or 
medical treatment also is enforced in the majority of most states. 
Certain states and localities have special programs that provide reimbursement for medical therapy, including 
antiretroviral medication after sexual assault, and those areas might have specific reporting requirements. In all 
states, sexually assaulted persons are eligible for reimbursement of medical expenses through the U.S. 
Department of Justice Victim’s Compensation Program in cases where the sexual assault is reported to the 
police (http://www.ojp.usdoj.gov/ovc/map.html).When the sexual abuse of a child is suspected or documented, 
the clinician should report it in compliance with that jurisdiction’s laws and regulations.  
VII-F2. Special Populations  
VII-F2a. Sexually Assaulted Persons  
Eighteen percent of a national sample of adult women in the United States reported having ever been raped, and 
approximately 1 in 10 women (9.4%) has been raped by an intimate partner during her lifetime.189 Sexual 
assault also occurs among men. Approximately 1 in 71 men (1.4%) in the United States has been raped at some 
time in his life.189 In 1 series from an ED, 5% of reported rapes involved men sexually assaulted by men.190 
Sexual assault typically has multiple characteristics that increase the risk for HIV transmission if the assailant is 
infected. In 1 prospective study of 1,076 sexually assaulted person, 20% had been attacked by multiple 
assailants, 39% had been assaulted by strangers, 17% had had anal penetration, and 83% of females had been 
penetrated vaginally. Genital trauma was documented among 53% of those assaulted, and sperm or semen was 
detected in 48%.191 Often, in both stranger and intimate-partner rape, condoms are not used192,193 and STIs are 
frequently contracted.194-197 In the largest study198 examining prevalence of HIV infection among sexual 
assailants, 1% of men convicted of sexual assault in Rhode Island were HIV infected when they entered prison, 
compared with 3% of all prisoners and 0.3% of the general male population. 
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Persons provided nPEP after sexual assault or child sexual abuse should be examined and co-managed by 
professionals specifically trained in assessing and counseling patients and families during these circumstances 
(e.g., Sexual Assault Nurse Examiner [SANE] program staff). Local SANE programs can be located at 
http://www.sane-sart.com/. Patients who have been sexually assaulted will benefit from supportive services to 
improve adherence to nPEP if it is prescribed, and from crisis, advocacy, and counseling services provided by 
sexual assault crisis centers.  
VII-F2b. Pregnant Women and Women with Childbearing Potential  
Information is being collected regarding safe use of antiretroviral drugs for pregnant and breastfeeding women 
who do not have HIV infection, particularly those whose male partners have HIV infection and who use 
antiretrovirals as PrEP.114 Because considerable experience has been gained in recent years in the safe and 
recommended use of antiretroviral medications during pregnancy and breastfeeding among women with HIV 
infection—either for the benefit of the HIV-infected woman’s health or to prevent transmission to newborns—
and because of the lack of similar experience in HIV-uninfected pregnant women, nPEP drug recommendations 
(Table 5) rely on those used for HIV-infected women during pregnancy and breastfeeding.  
Health care providers should be aware that certain medications are contraindicated for use as nPEP among 
potentially or actually pregnant women as follows (Table 7): 
• Efavirenz (EFV) is classified as FDA pregnancy Category D because of its potential teratogenicity when 
used during the first 5–6 weeks of pregnancy.199 It should be avoided in nPEP regimens for HIV-
uninfected women during the first trimester and should not be used for women of childbearing age who 
might become pregnant during an antiretroviral prophylaxis course. For all women with childbearing 
potential, pregnancy testing must be done before the EFV initiation, and women should be counseled 
regarding potential risks to the fetus and the importance of avoiding pregnancy while on an EFV-
containing regimen.114  
• Prolonged use of stavudine (d4T) in combination with didanosine (DDI) for HIV-infected pregnant 
women has been associated with maternal and fetal morbidity attributed to lactic acidosis; therefore, this 
combination is not recommended for use in an nPEP regimen during pregnancy.123,124  
• Because using indinavir (IDV) is associated with increased risk for nephrolithiasis among pregnant 
women and its use without co-administration of a ritonavir as a boosting agent can result in substantially 
decreased plasma levels of IDV (the active agent) among pregnant women, IDV should not be used as 
nPEP for pregnant women. 
• Severe hepatotoxicity has been observed among patients administered nevirapine (NVP)-containing 
nPEP regimens (regardless of pregnancy status); therefore, NVP is contraindicated for nPEP, including 
for pregnant women.83 
Table 7. Antiretroviral medications that should not be used for nPEP among pregnant women  
Antiretroviral Risk in pregnancy Concern 
Efavirenz Teratogenicity  Fetal safety 
Nevirapine Hepatotoxicity  Maternal safety 
Stavudine and didanosine Mitochondrial toxicity and lactic acidosis Maternal safety 
Indinavir (without co-administration with 
ritonavir) during second or third trimester 
Substantially decreased plasma concentration; risk for 
nephrolithiasis 
Efficacy and maternal safety 
Abbreviation: nPEP, nonoccupational postexposure prophylaxis. 
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If nPEP is prescribed to a woman who is pregnant at the time of exposure or becomes pregnant while on nPEP, 
health care providers should enter the patient’s information (anonymously) into the Antiretroviral Pregnancy 
Registry (http://www.apregistry.com). 
VII-F2c. Incarcerated Persons 
Approximately 2 million persons are incarcerated in jails and prisons and can be at risk for HIV infection 
acquisition during incarceration. Studies have indicated that the risk for becoming infected while incarcerated is 
probably less than the risk outside a facility200-202; nevertheless, correctional facilities should develop protocols 
for nPEP to help reduce the legal, emotional and medical problems associated with an exposure event for this 
vulnerable population. As foundation for nPEP provision when it is indicated, correctional facilities should 
provide HIV education, voluntary HIV testing, systems to assist in identifying potential HIV exposures without 
repercussion for inmates, and provision of nPEP evaluation and medication. Sexual assaults in particular can 
put inmates at risk for HIV acquisition and inmates may engage in behaviors that put them at risk for HIV 
acquisition both prior to being incarcerated and upon reentry into the community. A 15-minute interactive 
educational program designed to educate inmates about nPEP resulted in a 40% increase in knowledge 
compared to baseline regardless of inmate-related demographics or HIV-risk characteristics.203  
The federal Bureau of Prisons has published a clinical practice guideline that integrates guidance for 
nonoccupational and occupational HIV-related exposures.204 Those guidelines specific to nPEP represent an 
adaptation of the 2005 CDC nPEP guidelines and outline HIV postexposure management recommendations for 
the different exposure types. The federal Bureau of Prisons nPEP recommendations can be modified for use in 
correctional facilities of varying sizes and resources. The Bureau of Prisons guidelines provide practical 
materials for both correctional health care providers and inmates and include worksheets to assist health care 
providers in systematically documenting HIV exposures and nPEP therapy management, and sample patient 
consent forms. They recommend that each correctional facility develop its own postexposure management 
protocol. The CDC recommends that health care providers should make every effort to use of current CDC 
guidelines related to selection of nPEP antiretrovirals.  
VII-F2d. PWID 
A history of injection drug use should not deter health care providers from prescribing nPEP if the exposure 
provides an opportunity to reduce the immediate risk for acquisition of HIV infection. A survey of health care 
providers who treat PWID determined a high degree of willingness to provide nPEP after different types of 
potential HIV exposure.202  
When evaluating whether exposures are isolated, episodic, or ongoing, health care providers should assess 
whether persons who continue to engage in injecting or sexual HIV risk behaviors are practicing risk reduction 
(e.g., not sharing syringes, using a new sterile syringe for each injection, and using condoms with every partner 
or client). For certain persons, a high-risk exposure might be an exceptional occurrence and merit nPEP despite 
their ongoing general risk behavior. For other persons, the risk exposures might be frequent enough to merit 
consideration of PrEP either instead of nPEP or after a 28-day nPEP course.  
PWID should be assessed for their interest in substance abuse treatment and their knowledge and use of safe 
injecting and sexual practices. Patients desiring substance abuse treatment should be referred for such treatment. 
Persons who continue to inject or who are at risk for relapse to injection drug use should be instructed regarding 
use of a new sterile syringe for each injection and the importance of avoiding sharing injection equipment. In 
areas where programs are available, health care providers should refer such patients to sources of sterile 
injection equipment. When sexual practices can result in ongoing risk for HIV acquisition, referral for sexual 
risk-reduction interventions is recommended. 
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None of the preferred or alternative antiretroviral drugs recommended for nPEP in Table 5 have substantial 
interactions with methadone or buprenorphine. However, other antiretrovirals might decrease or increase 
methadone levels; therefore, health care providers electing to use antiretrovirals not specifically recommended 
for nPEP should check for interactions before prescribing to persons on opiate substitution therapy. 
For example, RTV-boosted DRV can decrease methadone levels marginally (within acceptable clinical range), 
and careful monitoring for signs and symptoms of withdrawal is advised.205 
VII-F3. Special Legal and Regulatory Concerns  
VII-F3a. HIV Testing of Exposure Source Patients 
When approaching persons who were the exposure source for patients being considered for nPEP, health care 
providers should be aware of potential legal concerns related to requesting them to undergo HIV testing. During 
2011, a total of 33 states had ≥ 1 HIV-specific criminal exposure laws.206 These laws focus explicitly on persons 
living with HIV. HIV-specific criminal laws criminalize or impose additional penalties on certain behaviors 
(e.g., sexual activity or needle-sharing without disclosure of HIV-positive status) and sex offenses. In 
jurisdictions where consent to HIV testing might invoke legal repercussions (see 
http://www.cdc.gov/hiv/policies/law/states/), the exposure source person should be made aware of possible 
legal jeopardies. Health care providers can opt instead to make nPEP treatment decisions without HIV testing of 
the source. 
VII-F3b. Adolescents and Clinical Preventive Care 
Health care providers should be aware of local laws and regulations that govern which clinical services 
adolescent minors can access with or without prior parental consent. In certain jurisdictions, minors of 
particular ages can access contraceptive services, STI diagnosis and treatment, or HIV testing without parental 
or guardian consent. In fewer settings, minors can access clinical preventive care (e.g. vaccines, nPEP, or 
PrEP).207 To provide and coordinate care when a minor presents for possible nPEP, health care providers should 
understand their local regulations and institutional policies guiding provision of clinical preventive care to 
adolescent minors. 
VII-F4. Potential Sources of Financial Assistance for nPEP Medication 
Antiretroviral medications are expensive, and certain patients are unable to cover the out-of-pocket costs. When 
public, privately purchased, or employer-based insurance coverage is unavailable, health care providers can 
assist patients with obtaining antiretroviral medications through the medication assistance programs of the 
pharmaceutical companies that manufacture the prescribed medications. Applications are available online that 
can be faxed to the company or certain companies can be called on an established phone line. Requests for 
assistance often can be handled urgently so that accessing medication is not delayed. Information for specific 
medications and manufacturers is available at 
http://www.pparx.org/en/prescription_assistance_programs/list_of_participating_programs. 
Additionally, persons being prescribed nPEP after sexual assault can be reimbursed for medications and clinical 
care costs through state Crime Victim’s Compensation Programs funded by the U.S. Department of Justice. 
Contact information for each state is available at http;//www.ojp.usdoj.gov/ovc/map.html or 
http;//www.nacvcb.org/index.asp?bid=16. 
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VIII. CONCLUSION 
Accumulated data from human clinical and observational studies, supported by data from animal studies, 
indicate that using antiretroviral medication initiated as soon as possible ≤72 hours after sexual, injection drug 
use, or other substantial nonoccupational HIV exposure and continued for 28 days might reduce the likelihood 
of HIV acquisition. Because of these findings, DHHS recommends prompt initiation of nPEP with a 
combination of antiretroviral medications when persons seek care ≤72 hours after exposure, the source is known 
to be HIV infected, and the exposure event presents a substantial risk for HIV acquisition by an exposed, 
uninfected person. When the HIV status of the source is unknown and the patient seeks care ≤72 hours after 
exposure, DHHS does not recommend for or against nPEP, but encourages health care providers and patients to 
weigh the risks and benefits on a case-by-case basis. When the HIV acquisition risk is negligible or when 
patients seek care > 72 hours after a substantial exposure, nPEP is not recommended. A 3-drug nPEP regimen is 
recommended for all persons for whom nPEP is indicated. Providing a 28-day nPEP supply or a 3–7 day nPEP 
starter pack at initiation of nPEP might improve adherence. Providing medications to ameliorate specific side 
effects for the antiretrovirals prescribed might improve adherence to the nPEP regimen. Figure 2 includes a 
summary of key nPEP considerations.  
Figure 2. nPEP considerations summary 
Initial nPEP Evaluation 
— Obtain history of potential exposure event 
 HIV and HBV status of exposed person and source person, if available 
 Timing of most recent potential exposure 
 Type of exposure event and risk for HIV acquisition 
 Make determination if nPEP is indicated 
— If nPEP is indicated 
 Conduct laboratory testing 
– HIV blood test (rapid combined Ag/Ab test, if available) 
– STIs, HBV, HCV, pregnancy, and chemistries, as indicated 
 Prescribe 28-day nPEP course 
– Educate patient about potential regimen-specific side effects and adverse events 
– Counsel patient about medication adherence 
– Provide patient with nPEP prescription or full 28-day nPEP course or nPEP starter pack and prescription 
 When necessary, assist patients with obtaining nPEP medication through a medication assistance program for the prescribed regimen 
— For all persons evaluated 
 Prescribe prophylaxis for STIs and HBV infection, if indicated 
 Provide counseling related to HIV prevention strategies, as appropriate 
 Document sexual assault findings and fulfill local reporting requirements 
 Conduct confidential reporting of newly diagnosed STIs and HIV infection to health department 
 Link HIV-infected persons to relevant medical and psychosocial support services 
Follow-up evaluations for persons prescribed nPEP 
— Conduct HIV and any other indicated laboratory testing 
— Consider changing nPEP regimen if indicated by side effects or results of initial testing 
— Provide additional counseling and support for medication adherence and HIV prevention, if indicated 
Abbreviations: Ag/Ab, antigen/antibody combination test; HBV, hepatitis B virus; HCV, hepatitis C virus; HIV, human immunodeficiency virus; nPEP, 
nonoccupational postexposure prophylaxis; STI, sexually transmitted infection. 
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VIII-A. Plans for Updating These Guidelines 
These guidelines are intended to assist U.S. health care providers in reducing the occurrence of new HIV 
infections through the effective delivery of nPEP to the patients most likely to benefit. As new medications and 
new information regarding nPEP become available, these guidelines will be revised and published.  
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Appendix 1A 
Summary of Methods for nPEP Guidelines Development and Roles of Teams and Consultants 
Topic Comment 
The guidelines’ goal Provide guidance for medical practitioners regarding nPEP use for persons in the United States. 
nPEP Working Group The nPEP Working Group is composed of 13 members from the Centers for Disease Control and Prevention (CDC) with 
expertise in nPEP or other subject areas pertinent to the guidelines (e.g., cost-effectiveness, sexual assault, or nPEP adherence), 
including certain members who were involved in the writing of the previous version(s) of the CDC nPEP guidelines.  
nPEP Writing Group The nPEP Writing Group is composed of 12 members from CDC with expertise in nPEP or other subject areas pertinent to the 
guidelines (e.g., cost-effectiveness, sexual assault, or nPEP adherence, etc.), including 1 member who was involved in the writing 
of the previous version of CDC’s nPEP guidelines. 
nPEP external 
consultants 
External consultants were selected from government, academia, and the health care community by CDC to participate in 2 
consultations by telephone conference call regarding nPEP on the basis of the member’s area of subject matter expertise. Each 
consultation was chaired by 1 of the CDC nPEP co-chairs. The list of the external consultants is available in Appendix 2B. 
Competing interests and 
management of conflicts 
of interest  
All internal CDC staff and external consultants involved in developing the guidelines or who served in the external consultations 
submitted a written financial disclosure statement reporting any potential conflicts of interest related to questions discussed during 
the consultations or concerns involved in developing of the nPEP guidelines. A list of these disclosures and their last update is 
available in Appendix 2C. The nPEP co-chairs reviewed each reported association for potential competing interest and 
determined the appropriate action, as follows: disqualification from the panel, disqualification/recusal from topic review and 
discussion; or no disqualification needed. A competing interest is defined as any direct financial interest related to a product 
addressed in the section of the guideline to which a panel member contributes content. Financial interests include direct receipt 
by the panel member of payments, gratuities, consultancies, honoraria, employment, grants, support for travel or accommodation, 
or gifts from an entity having a commercial interest in that product. Financial interest also includes direct compensation for 
membership on an advisory board, data safety monitoring board, or speakers bureau. Compensation and support that filters 
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Topic Comment 
OMB Peer Review and 
OMB Public Engagement 
As recommended by the Office of Management and Budget for scientific documents fitting the classification of Influential Scientific 
Information, during Oct. 2014–December 2015, the draft nPEP guidelines underwent peer review by independent scientific and 
technical experts. They were asked to review the scientific and technical evidence that provides the basis for the nPEP guidelines 
and to provide input on the draft guidelines before they were finalized. Peer reviewers were asked whether any recommendations 
are based on studies that were inappropriate as supporting evidence or were misinterpreted, whether there are significant 
oversights, omissions, or inconsistencies that are critical for the intended audience of clinicians, and whether the 
recommendations for the intended audience of health care providers are justified and appropriate. In addition, the 
recommendations from the draft nPEP guidelines were presented to the public through 2 public engagement webinars on 
November 14 and 17, 2014. Based on the responses from both peer review and public engagement, updates were made to the 
nPEP guidelines prior to their publication. CDC’s responses to the comments were also posted on the CDC/ATSDR Peer Review 
Agenda website at http://www.cdc.gov/od/science/quality/support/peer-review.htm and the CDC Division of HIV/AIDS Prevention 
Program Planning Scientific Information Quality—Peer Review Agenda website at http://www.cdc.gov/hiv/policies/planning.html. 
Guidelines users Health care providers 
Developer The CDC nPEP Working Group 
Funding source Epidemiology Branch, Division of HIV/AIDS Prevention, National Center for HIV/AIDS, Viral Hepatitis, STD, TB Prevention, CDC 
Recommendation ratings Because none of the evidence is based on randomized clinical trials, but rather observational studies or expert opinion, we have 
elected not to provide graded recommendations for these guidelines. 
Abbreviations: AIDS, acquired immunodeficiency virus; CDC, Centers for Disease Control and Prevention; HIV, human immunodeficiency virus; 
nPEP, nonoccupational postexposure prophylaxis. 
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Appendix 2 
Literature Search Methods for the nPEP Guidelines 
 
Topic Databases Research Question Keywords Dates of Search Search Limits 
Animal Studies PubMed Which studies related to PEP involving 
animal models were published since 2005? 
SIV post exposure prophylaxis, post-
exposure prophylaxis, antiretroviral 
prophylaxis in macaques 
January 2005 to July 2015 No limitations 
Observational Studies, Case Reports Web of Knowledge, PubMed, 
Google Scholar 
Which are the results of latest nPEP 
observational and case studies since 2005 
with a focus on populations studied, drug 
regimens used, completion rates, side 
effects of medications, number of 
breakthrough infections? 
nPEP, nonoccupational postexposure or 
post-exposure prophylaxis, and HIV 
postexposure or post-exposure prophylaxis 
January 2005 to July 2015 Excluded opinion pieces; no other 
limitations 
Effects on Risk-Reduction Behaviors MEDLINE, EMBASE, CINAHI 
[EBSCOhost] 
What are the potential behavioral 
implications of offering nPEP?  
HIV infections, acquired immune deficiency 
syndrome, seropositivity, serodiagnosis, 
HIV, AIDS, post exposure or post-exposure 
prophylaxis, post exposure or post-
exposure prevention, non-occupational, 
non pep, NOPEP, nPEP, PEP  
January 1996 to July 2015 No limitations 
Cost Effectiveness PubMed The cost-effectiveness evaluation of nPEP in 
the United States and other resource-rich 
countries. 
HIV, post exposure post-exposure 
prophylaxis, PEP, nPEP, economic 
evaluation, cost utility, cost-benefit 
analysis, cost benefit, cost effectiveness  
January 2005 to July 2015 English only; excluded occupational 
exposure; not an economic 
evaluation; no other limitations 
Pregnant Women, Women of 
Childbearing Potential 
PubMed Which nPEP studies involving pregnant 
women and women of childbearing potential 
were conducted since 2005? 
pregnant women, women of reproductive 
age, PEP, nPEP, postexposure or post-
exposure HIV prophylaxis 
January 2005 to July 2015 No limitations 
Children/Adolescents PubMed Which nPEP studies involving children or 
adolescents were conducted since 2005? 
Children, pediatrics, adolescents, PEP, 
nPEP, postexposure or post-exposure HIV 
prophylaxis 
January 2005 to July 2015 No limitations 
Sexual Assault Survivors PubMed Which nPEP studies involving sexual assault 
survivors were conducted since 2005? 
Sexual assault, sexual abuse, PEP, nPEP, 
postexposure or post-exposure HIV 
prophylaxis 
January 2005 to July 2015 No limitations 
Incarcerated Populations PubMed Which nPEP studies involving incarcerated 
populations were conducted since 2005? 
Incarcerated, jail, prison, correctional 
facility, nPEP, PEP 
January 2005 to July 2015 No limitations 
Abbreviations: AIDS, acquired immunodeficiency syndrome; HIV, human immunodeficiency virus; nPEP, non-PEP, or NOPEP, nonoccupational postexposure prophylaxis; PEP, postexposure prophylaxis. 
 
2016 nPEP Guidelines Update Page 68 of 91 
Appendix 3 
Studies Reviewed for the nPEP Guidelines 
MSM Studies  
Authors, year: Donnell et al, 201014 
Type of study: Randomized behavioral intervention trial to assess perceptions and nPEP use over a 4-year period 
Location: 6 U.S. cities 
Sample size: n = 4,295 MSM 
Risk: HIV uninfected men who reported unprotected anal sex in the past year 
Intervention: Behavioral intervention vs. standard risk-reduction counseling (accompanying nPEP drug regimen not reported) 
Drug regimen: Not reported 
Time from exposure to nPEP: Not reported 
Completion of nPEP: Not reported 
HIV seroconversions: 3 
Conclusion: Increased odds of nPEP use was observed in participants with multiple partners and participants who had unprotected anal sex with HIV infected and 
unknown status partners. The availability of nPEP did not lead to an increase in high-risk sex. 
Authors, year: Foster et al, 201519 
Type of study: Open-label, single-arm nonrandomized trial at 2 public sexual health clinics and 2 hospital EDs during December 23, 2012–June 12, 2014. 
Location: Melbourne, and Sydney, Australia 
Sample size: n = 100 MSM 
Risk: Sexual 65% failed to use a condom after anal intercourse; 29% used a condom but it tore or slipped off; 6% source partner removed condom 
Intervention: 3-drug single tablet once daily dose regimen 
Drug regimen: RPV + FTC + TDF 
Time from exposure to nPEP: ≤ 72 hours; presentation for nPEP initiation at a mean = 30 hours; nPEP initiated at a mean of 2 hours after presentation 
Completion of nPEP: 92% 
HIV seroconversions: 0 seroconversions occurred through week 12 after initiation of nPEP. Adherence was 98.6% by pill count and 98.5% by self–report; 88% 
tested had plasma TDF levels suggesting full adherence. 88% experienced ≥ 1 clinical adverse events. Adverse events included mainly fatigue (34%) and nausea 
(23%); one participant developed acute abdominal pain and vomiting and grade 4 laboratory evidence of acute pancreatitis ≤ 1 week of completing nPEP.  
Conclusion: A triple ARV regimen of RPV, FTC, and TDF administered once daily as a single combination tablet was well tolerated as nPEP with high levels of 
adherence and regimen completion. 
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Authors, year: Jain et al, 201518 
Type of study: Retrospective medical record review in a large community health center during July1997–August 2013 
Location: Boston, Massachusetts 
Sample size: n = 788 MSM; median age = 32.9 years; 21.2% presented for nPEP 2 or more times (range, 1–15 times) 
Risk: Consensual unprotected sex most common n = 726 (62.2%); n = 425 (58.5%) receptive anal; n = 277 (38.2%) insertive anal; n = 157 (21.6%) receptive oral 
intercourse; n = 351 (31.1%) condom failure or removal; (35.6%) HIV-positive partner 
Intervention: nPEP (number of drugs not reported in this study, however, previous studies from this site have reported 2 or 3 drugs) 
Drug regimen: Not reported 
Time from exposure to nPEP: Not reported but assume 72 hours based on previously published studies from this site 
Completion of nPEP: Not reported 
HIV seroconversions: 39 seroconversions occurred at > 90 days after initially presenting for nPEP; 4 occurred at < 180 days: 91, 133, 160, 168 days; 3 of 4 
reported completing 28-day regimen; adherence or ongoing sexual risk behavior not reported; 35 (89.7%) seroconversions occurred at ≥ 180 days after nPEP 
initiation; seroconversion associated with younger age and/or being African American or Latino; almost 90% of post-nPEP infections were probably due to 
subsequent risk-taking and not a failure of the initial nPEP regimen 
Conclusion: Younger age, being Latino and/or being African American, but not repeated nPEP use, were associated with incident HIV infection. Younger MSM 
of color who are nPEP users may benefit from early HIV risk reduction and PrEP. 
Authors, year: McAllister et al, 201417 
Type of study: Nonrandomized, open-label, prospective cohort study at two urban hospital centers 
Location: Sydney, Australia 
Sample size: n = 125 MSM enrolled; n = 91 prescribed 3-drug regimen; n = 34 prescribed 2-drug regimen; mean age 32–34 years 
Risk: Sexual 
Intervention: 2-drug or 3-drug regimen 
Drug regimen: TDF + FTC or RAL+ TDF + FTC; Mean Adherence to each arm: TDF + FTC (90%); RAL-FTC-TDF (89%); 8 patients reported myalgia on the 
3-drug regimen vs. none on the 2-drug regimen; Grade 4 creatinine kinase elevations occurred in 5 subjects on the 3-drug regimen vs. none on the 2-drug regimen. 
All Grade 4 creatinine kinase elevations resolved to ≤ grade 2 after desisting from exercise and increasing oral fluids intake 
Time from exposure to nPEP: Not reported 
Completion of nPEP: 86/91 (95%) participants prescribed a 3-drug regimen met criteria to stay on nPEP; 79/86 (92%) completed 28-day 3-drug regimen; 31/34 
(91%) participants prescribed 2-drug regimen completed 28-day 2-drug regimen; overall 110/120 (91.7%) who met criteria to stay on nPEP completed 28-day 
regimen; overall 110/125 (88%) who were prescribed nPEP, completed the 28-day regimen 
HIV seroconversions: 0 
Conclusion: Although the 3-drug and 2-drug arms had similar percentages of patients completing their 28-day regimens, 9% of the 3-drug arm experienced grade 
4 creatinine kinase elevations which subsequently resolved with increased fluid intake and desisting exercise. If a RAL-TDF-FTC regimen is used, a preferred 
nPEP regimen, authors recommend (1) asking patients about concomitant medications associated with rhabdomyolysis (i.e. statins); (2) patient education about 
possible association between RAL-containing nPEP, exercise, and rhabdomyolysis and the need to report myalgia; (3) laboratory monitoring of serum creatinine 
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kinase at baseline; if myalgia or weakness develops, conduct additional during treatment and clinical examination for proximal muscle weakness. Completion rates 
were higher for this study compared to those in other studies, including similar nPEP regimens. This may have been due to a high level of support provided by the 
study team including an experienced nPEP nurse, 24-hour contact with the nurse consultant, text reminders of appointments, proactive recall after missed 
appointments and frequent adherence education. 
Authors, year: Schechter et al, 200416 
Type of study:  
Location: Rio de Janeiro, Brazil 
Sample size: n = 200 participants; median age, 28 years; n = 68 received nPEP 
Risk: Sexual exposure (gay or bisexual) 
Intervention: 2-drug regimen 
Drug regimen: ZDV + 3TC 
Time from exposure to nPEP: ≤ 48 hours 
Completion of nPEP: 11 (1 among nPEP users, 10 among patients not using nPEP) 
HIV seroconversions:  
Conclusion: nPEP was safely tolerated and did not appear to be associated with either increases in reported high-risk behavior or HIV transmission; such findings 
may limit its impact as a public health intervention 
Authors, year: Sonder et al, 201015 
Type of study: Observational study comparing 2 nPEP regimens 
Location: Amsterdam 
Sample size: n = 309 MSM 
Risk: Sexual exposure 
Intervention: One 4-drug regimen and one 3-drug regimen; 2- or 3-pill burden 
Drug regimen: Single-dose NVP + ZDV+ 3TC+ NFV or ZDV + 3TC + ATV 
Time from exposure to nPEP: Seroconverters presented between 5–36 hours post exposure 
Completion of nPEP: 237/261 (91%) 
HIV seroconversions: 5 (likely due to ongoing risk behavior) 
Conclusion: Common side effects were fatigue, nausea, and diarrhea (worse in regimen 1). There was no significant difference in completion rates of the two 
regimens. Strategies are needed to prevent subsequent HIV exposures in nPEP-treated individuals 
Authors, year: Terzi et al, 200713 
Type of study: Case report 
Location: Italy 
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Sample size: n = 1 MSM 
Risk: Receptive anal intercourse with HIV + male 
Intervention: 3-drug regimen; 2-pill burden 
Drug regimen: ZDV + 3TC (Combivir) + IDV 
Time from exposure to nPEP: 30 hours 
Completion of nPEP: Complete adherence 
HIV seroconversions:  
Conclusion: Sexual exposures to HIV and HCV require prolonged follow-up due to the risk of late seroconversion. 
Sexual Assault Studies—Adults, Adolescents, and Children (combined) 
Authors, year: Chacko et al, 201220 
Type of study: Systematic review of nPEP adherence among victims of sexual assault 
Location: U.S. and International 
Sample size: n = 24 studies of adults, adolescents, and children 
Risk: Sexual assault 
Intervention: Various 2- and 3-drug regimens 
Drug regimen: Most regimens included ZDV 
Time from exposure to nPEP: Not reported 
Completion of nPEP: 40% 
HIV seroconversions: Not reported 
Conclusion: Overall adherence was poor but was higher in developing countries compared to developed countries. Common side effects were: nausea and 
vomiting, diarrhea, and fatigue. More interventions are needed to improve adherence. Standard methods of conducting and reporting nPEP programs are needed. 
Authors, year: Draughon and Sheridan, 201121 
Type of study: Systematic review spanning 10 years 
Location: Sub-Saharan Africa (Kenya, Malawi, and South Africa) 
Sample size: n = studies of adults, adolescents, and children 
Risk: Sexual assault 
Intervention: Not reported 
Drug regimen: Not reported 
Time from exposure to nPEP: Not reported 
Completion of nPEP: 0%–65% (most studies reported > 35%) 
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HIV seroconversions: Not reported 
Conclusion: Overall adherence was low, but was higher in locations where the full 28-day PEP regimen was given up front. 
Authors, year: Draughon and Sheridan, 201222 
Type of study: Systematic review 
Location: Low HIV prevalence countries 
Sample size: n = 34 studies of adults, adolescents, and children 
Risk: Sexual assault 
Intervention: nPEP (number of drugs not reported by reviewers) 
Drug regimen: Not reported 
Time from exposure to nPEP: 24–96 hours 
Completion of nPEP: 0%–63% 
HIV seroconversions: Not reported 
Conclusion: There was wide variation in the provision, acceptance, and adherence to nPEP programs. Anywhere from 5%–100% of eligible patients received 
nPEP across studies. Further research is needed to understand the experience of sexual assault survivors with the health care system and nPEP following an attack 
Authors, year: Loutfy et al, 200823 
Type of study: Prospective cohort study 
Location: Ontario, Canada 
Sample size: n = 798 sexual assault survivors presented to sexual assault treatment centers and offered nPEP; females (n = 775 [97.1%]), age 4–17 years (n = 190 
[23.8%]), age 18–80 years (n = 608 [77.2%]); 347 accepted nPEP 
Risk: Sexual assault 
Intervention: 3-drug regimen; 2-pill burden 
Drug regimen: Combivir + Kaletra 
Time from exposure to nPEP: ≤ 72 hours 
Completion of nPEP: 111/347 (31.9%) completed nPEP including (11/46 [23.9%]) of participants at high risk completed therapy and (100/301 [33.2%]) of 
unknown risk participants completed therapy 
HIV seroconversions: Not reported 
Conclusion: The PEP program for sexual assault survivors in Ontario proved to be feasible and acceptable among participants. The most common side effects 
were fatigue, nausea, and diarrhea. Further research is needed to improve loss to follow-up and completion rates of nPEP. 
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Sexual Assault Studies—Adults and/or Adolescents 
Authors, year: Carrieri et al, 200633 
Type of study: Retrospective survey of nPEP consultations 
Location: Southeastern France 
Sample size: n = 94 persons, aged 18 years or older, presented to AIDS centers for nonoccupational HIV exposure (female n = 88 [93.6%], male n = 6 [6.4%]); 
nPEP prescribed to 86 persons 
Risk: Sexual assault 
Intervention: 2 and 3 drug regimens 
Drug regimen: Not reported 
Time from exposure to nPEP: 72% (n = 77) ≤ 48 hours 
Completion of nPEP: 25% (n = 23) > 3 months follow-up 
HIV seroconversions: Not reported 
Conclusion: Half of all participants were lost to follow-up after the first consultation. During the study period there were 600 additional sexual assaults that were 
reported to police but did not receive nPEP consultation. Prompt HIV medical assessment is needed for sexual assault survivors as well as strategies to improve 
nPEP adherence. 
Authors, year: Griffith et al, 201031 
Type of study: Retrospective chart review in an urban county hospital from June 2007–June 2008 
Location: Dallas, TX 
Sample size: n = 151 adolescent and adult women (151 prescribed nPEP, 62 received follow-up of which 58 self-reported taking nPEP); aged 13–17 years, n = 43 
(28%); 18–61 years, n = 108 (72%) 
Risk: Sexual assault 
Intervention: 3-drug regimen; 2-pill burden 
Drug regimen: Kaletra + Truvada or Combivir 
Time from exposure to nPEP: ≤ 72 hours 
Completion of nPEP: 62/151 (41%) of women presented for a follow-up visit. 37 of the 62 (60%) took nPEP for ≥ 21 days or completed prescribed course of 
therapy 
HIV seroconversions: 0 (36 of 58 women who reported taking nPEP at follow-up were HIV screened at week 12 or 24 of follow-up) 
Conclusion: Full medication compliance and follow-up counseling remain challenges for sexual assault survivors and providers. A detailed nPEP protocol and 
continuity of care promotes quality patient management. 
Authors, year: Krause et al, 201434 
Type of study: Retrospective cohort study of medical records from a level 1 trauma center participating in the Sexual Assault Nurse Examiner (SANE) Program 
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Location: Northeastern, United States 
Sample size: n = 179 cases of sexual assault among 171 unique female patients, aged ≥ 16 years (median: 26 years); nPEP offered to 138 patients for whom PEP 
was appropriate within the 72-hour window period; an additional 5 patients outside the 72-hour window period were offered PEP; 86% or 124/143 cases who were 
offered PEP, accepted PEP 
Risk: Sexual assault 
Intervention: 2-drug or 3-drug regimen 
Drug regimen: Either FTC/TDF and LPV/r) (n = 85, 59.4%) or FTC/TDF alone (n = 32, 22.4%) 
Time from exposure to nPEP: ≤ 72 hours (for most cases; 5 cases were given nPEP outside the 72-hour window) 
Completion of nPEP: 34 of 124 (27.4%) cases who followed up with an infectious disease specialist completed nPEP 
HIV seroconversions: Not reported 
Conclusion: All 138 sexual assault case patients who were eligible for nPEP were offered nPEP. Only a minority of those who were documented to have followed 
up with an infectious disease specialist completed nPEP. There is a need for a better system for post-assault follow-up. 
Authors, year: Linden et al, 200530 
Type of study: Retrospective medical record review of female sexual assault survivors presenting to an urban ED during 10/1/99–9/30/2002 
Location: Boston, MA 
Sample size: n = 292 charts reviewed; n = 181 in final sample size; mean age 29.1 years (range, 18–82); n = 89 patients offered nPEP; n = 85 patients accepted 
Risk: Sexual assault 
Intervention: 2-drug or 3-drug regimen; 1- or 2-pill burden 
Drug regimen: Initiated in ED, ZDV + 3TC (Combivir) (n = 78); Combivir + NFV (n = 4); Initiated in referral clinic: 2-drugs (unspecified) (n = 2); 3-drugs 
(unspecified) (n = 1) 
Time from exposure to nPEP: Median time from assault to presentation in ED (10.1 hours; range, 0–24 hours) 
Completion of nPEP: Overall 18 of 85 (21%), including 15 of 82 (18%) of those initiated on nPEP in ED and 3 of 3 initiated on nPEP after being referred to 
another clinical care site 
HIV seroconversions: No seroconversions during follow-up period in 38 patients with at least 1 follow-up visit 
Conclusion: A minority of sexual assault survivors were offered nPEP and few completed full nPEP course. 
Authors, year: Olshen et al, 200632 
Type of study: Retrospective medical record review of adolescents presenting to urban pediatric EDs ≤ 72 hours of penetrating sexual assault in 2 academic 
medical centers during July 1, 2001 to June 30, 2003 
Location: Boston, MA 
Sample size: n = 177 adolescents aged 12–22 years; n = 145 adolescents with adequate documentation; n = 129 eligible for nPEP; n = 110 accepted nPEP; n = 85 
initiated nPEP 
Risk: Sexual assault 
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Intervention: 2-drug or 3-drug regimen 
Drug regimen: 3TC + ZDV (94%); 3TC +ZDV + NFV (3%); 3TC + ZDV + IDV (2%) 
Time from exposure to nPEP: ≤ 72 hours 
Completion of nPEP: 13/85 (15%) who initiated nPEP completed 28-day course; 37 returned for first follow-up visit 
HIV seroconversions: No seroconversions among 23 tested for HIV 
Conclusion: Poor rates of nPEP completion among adolescent sexual assault survivors. May be due to uncertainties regarding exposure, high rates of psychiatric 
comorbidity, and low rates of return for follow-up care. 
Sexual Assault Studies Including Children and/or Adolescents 
Authors, year: Chesshyre et al, 200943 
Type of study: Retrospective review of medical records from January 2005–February 2007 
Location: Blantyre, Malawi 
Sample size: n = 217 children and adolescents presented with history of sexual abuse; ages: n = 62 (29%) < 5 years; n = 113 (52%) 5–10 years; n = 42 (19%) 11–16 
years; n = 92 children were eligible for and received nPEP; n = 153 children were not offered nPEP because they presented > 72 hours or had chronic history of 
abuse 
Risk: Child sexual abuse 
Intervention: 2-drug regimen 
Drug regimen: ZDV + 3TC 
Time from exposure to nPEP: ≤ 72 hours 
Completion of nPEP: Not reported 
HIV seroconversions: No HIV seroconversions in any of the 92 children initiated on nPEP; 7/153 (5%) children who were not offered nPEP tested HIV+ 
Conclusion: The initiation of an nPEP program for child victims of sexual abuse led to increased numbers of such children presenting for nPEP services and is 
likely to have resulted in decreased HIV acquisition in this population. 
Authors, year: Collings et al, 200842 
Type of study: Prospective observational cohort of 200 consecutive cases of child rape referred for assessment to a state hospital, Oct–Dec 2004 
Location: KwaZulu-Natal, South Africa 
Sample size: n = 200 children and adolescents presenting with history of child rape; mean age 10.6 years (range, 1–17 years); 120 children eligible and offered 
nPEP; n = 64 children not eligible due to presentation > 72 hours; n = 113 followed by hospital; n = 7 referred to another nPEP provider 
Risk: Child sexual abuse 
Intervention: 2-drug regimen 
Drug regimen: ZDV + 3TC 
Time from exposure to nPEP: ≤ 72 hours 
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Completion of nPEP: 40/113 (35.5%) followed by hospital completed 28-day course 
HIV seroconversions: No seroconversions among 13/40 children returning for 3-month follow-up and 4/40 children returning at 6-month follow-up. 
Conclusion: Poor nPEP adherence and return for follow-up existed; further research is needed to identify reasons for such nonadherence and identify interventions 
to improve adherence. 
Authors, year: Du Mont et al, 200844 
Type of study: Retrospective analysis of data on female adolescent sexual assault survivors from the HIV PEP Project, an implementation and evaluation of a 
program of universal offering of nPEP to sexual assault victims of all ages in 18 hospital-based sexual treatment centers 
Location: Ontario, Canada 
Sample size: n = 386 sexually assaulted female adolescents; mean age 16.7 years (range, 12–19 years); n = 325 eligible for nPEP; 307 offered nPEP; n = 131 
accepted nPEP; the most common reason for declining nPEP was lack of concern about acquiring HIV; students, survivors with marked anxiety, and those 
encouraged by a health professional were more likely to accept PEP 
Risk: Sexual assault 
Intervention: 3-drug regimen; 2-pill burden 
Drug regimen: Combivir and Kaletra 
Time from exposure to nPEP: ≤ 72 hours 
Completion of nPEP: 34% (44/131) completed 28-day course nPEP; 47% (61/131) adhered to day 14; the most common side effects were nausea, fatigue, 
vomiting, and diarrhea; survivors who were white and had known their assailant < 24 hours were more likely to complete nPEP; most common reasons for stopping 
nPEP early: ARV side effects (73%), including most often nausea and fatigue 
HIV seroconversions: Permission not obtained to provide results of HIV testing 
Conclusion: Stronger health care provider recommendations needed for nPEP; need for training of health care providers to consistently offer and recommend 
nPEP to all those meeting established risk criteria. 
Authors, year: Ellis et al, 200537 
Type of study: Prospective study of children presenting to hospital with history of child sexual abuse during January, 1 2004 through December 31, 2004 
Location: Blantyre, Malawi 
Sample size: n = 64 children presented with history of sexual assault; median age 83 months (range, 22–180 months); n = 17 children eligible for, offered, and 
accepted nPEP 
Risk: Sexual assault 
Intervention: 2-drug regimen 
Drug regimen: AZT+3TC 
Time from exposure to nPEP: ≤ 72 hours 
Completion of nPEP: 11/17 (65%) accepting nPEP completed 28-day course 
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HIV seroconversions: Among nPEP users, no seroconversions among 11 who returned after 1 month, 7 who returned after 3 months, and 2 who returned at 6 
months; 1 of 4 children who did not receive nPEP was screened for HIV and was HIV+ 
Conclusion: The study found nPEP to be safe, acceptable, and feasible. The authors recommend routine offering of nPEP to all eligible children. 
Authors, year: Fajman et al, 200641 
Type of study: Retrospective study of medical records of children presenting with child sexual abuse to inner-city pediatric ED in 2002 
Location: Atlanta, GA 
Sample size: n = 227 sexually assaulted children and adolescents with adequate data; age range, 9 months–18 years; n = 87 presented ≤ 72 hours of assault; n = 5 
sexually assault adolescent survivors were prescribed nPEP; being assaulted by a stranger associated with receiving nPEP (PR = 11.9, 95% CI = 1.4, 100.2, 
P = 0.02). 
Risk: Sexual assault 
Intervention: 3-drug regimen; 2-pill burden 
Drug regimen: Combivir (ZDV + 3TC) + nelfinavir 
Time from exposure to nPEP: Within 72 hours 
Completion of nPEP: 0 completed 28-day course 
HIV seroconversions: No seroconversions reported among the 3 nPEP recipients who were tested, or among the 82 patients who presented within 72 hours but 
did not receive nPEP 
Conclusion: nPEP for pediatric HIV exposures was underutilized in a hospital in a large urban center with high HIV prevalence and underscores the need for 
physician education about nPEP for children. 
Authors, year: Girardet et al, 200935 
Type of study: Retrospective medical record review of children and adolescents presenting at a sexual abuse clinic during a 38-month period (January 2001–
March 2004) 
Location: Houston, Texas 
Sample size: Of 4,234 cases of child or adolescent sexual assault, 1,750 (41%) were tested for HIV; n = 879 aged < 13 years, n = 871 adolescents; n = 303 were 
nPEP eligible; 16/303 (5%) were offered nPEP (aged 3–17 years); n = 15 accepted nPEP 
Risk: Sexual assault 
Intervention: 2- or 3-drug regimen 
Drug regimen: ZDV + 3TC (14 cases); ZDV + 3TC +LPV/r (1 case of acute genital trauma) 
Time from exposure to nPEP: ≤ 96 hours 
Completion of nPEP: Inconsistent reporting; none of the children completed follow-up; no reported significant side effects among the 9 patients reporting for at 
least 1 follow-up visit 
HIV seroconversions: No seroconversions among 9 children who returned for ≥ 1 follow-up visit 
Conclusion: Only 5% of those children or adolescents who were eligible for nPEP were offered nPEP. Adherence was difficult to document based on limited 
adherence to follow-up visits. Need for research to better define nPEP efficacy in children and adolescents. 
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Authors, year: Merchant et al, 200439 
Type of study: Retrospective medical record review of female adolescents presenting at an urban pediatric ED (January 1999 to December 2000) 
Location: New York, New York 
Sample size: n = 25 adolescent females aged 12–19 years presenting with history of sexual assault; n = 15 eligible for and offered nPEP; n = 14 accepted nPEP 
Risk: Sexual assault 
Intervention: 1- or 3-drug regimen 
Drug regimen: 1 received ZDV in 1999; 13 received 3-drug regimen, ZDV + 3TC + 3rd drug (n = 12); d4T + 3TC + 3rd drug (n = 1); (3rd drug was NFV [n = 9] or 
IDV [n = 4]) 
Time from exposure to nPEP: ≤ 72 hours; nPEP ordered an average of 218 minutes after patient presented to the ED; patient received drugs on average 58 
minutes after nPEP was ordered 
Completion of nPEP: No patients completed 28-day course 
HIV seroconversions: Not reported (efficacy not studied in this study) 
Conclusion: There was a significant delay in ordering nPEP and administering nPEP in the emergency room. Highlights importance of expediting nPEP in that 
setting. 
Authors, year: Neu et al, 200738 
Type of study: Prospective nonrandomized observational study of children and adolescents presenting to the pediatric ED during March 1999–September 2002 
Location: New York City, New York 
Sample size: n = 70 patients (aged 11–19 years) evaluated for sexual assault; n = 33 enrolled in the study (94% female; mean age 15.3 years) 
Risk: Sexual assault 
Intervention: 2-drug regimen; 1-pill burden 
Drug regimen: Combivir 
Time from exposure to nPEP: ≤ 72 hours 
Completion of nPEP: 8/33 (24%); return rate for follow-up visits: 1st visit, 23/33 (70%); week 2, 20/33 (60%); week 4–6, 11/33 (33%); 12 weeks, 9/33 (27%); 24 
weeks, 6/33 (18%) 
HIV seroconversions: No seroconversions in those presenting for follow-up at 4–6 weeks (11/33), 12 weeks (9/33), or 24 weeks (6/33) 
Conclusion: Inadequate adherence to medications and follow-up were significant problems in this nPEP program for sexually assaulted children and adolescents. 
Authors, year: Schremmer et al, 200536 
Type of study: Retrospective medical record review of children presenting for evaluation of suspected sexual abuse who were provided nPEP during February 
1999–March 2001. 
Location: Kansas City, Missouri 
Sample size: n = 2,865 evaluated for suspected sexual abuse; n = 34 children and adolescents received nPEP (aged 12 weeks to 18 years, mean age 13 years); nPEP 
use associated with stranger assault 
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Risk: Sexual abuse 
Intervention: 1-, 2-, and 3-drug regimens 
Drug regimen: ZDV (n = 1); ZDV + 3TC (n = 32); ZDV+3TC+NFV (n = 1) 
Time from exposure to nPEP: ≤ 73 hours (range, 2–73 hours) 
Completion of nPEP: 8/34 (24%) patients completed 28-day course 
HIV seroconversions: No seroconversions among 33 patients tested at initial evaluation or among the 16 patients who had at least 1 subsequent HIV test after 
initial evaluation 
Conclusion: Inadequate adherence to medication regimen and follow-up in child and adolescent survivors of suspected sexual abuse who received nPEP were 
noted. 
Authors, year: Speight et al, 200640 
Type of study: Retrospective medical record review of children presenting with suspected childhood rape to a sexual assault care center during July 2003–March 
2004 
Location: Thika, Kenya 
Sample size: n = 48 children aged < 18 years (96.8% female) presenting with suspected rape; n = 33 eligible for, offered, and accepted nPEP 
Risk: Sexual assault 
Intervention: 2-drug regimen 
Drug regimen: ZDV + 3TC 
Time from exposure to nPEP: ≤ 72 hours 
Completion of nPEP: 15/33 (45%) completed 28-day course 
HIV seroconversions: No seroconversions among 3 patients tested for HIV; 3 seroconversions among 15 who were not eligible for nPEP 
Conclusion: Majority (86%) of children presented within the 72-hour window period. Providing post-rape care is feasible and acceptable but requires special 
training for counselors, and providers, including training related to pediatric dosing. 
Pediatric and Adolescent Community-acquired Needlestick Injury (CA-NSI) Studies 
Authors, year: de Waal et al, 200666 
Type of study: Case report of nPEP use among children involved in a mass needlestick injury (1999) 
Location: Tygerberg, South Africa 
Sample size: n = 54 children involved in mass needlestick exposure from discarded needles on a soccer field; n = 44 were administered nPEP 
Risk: CA-NSI 
Intervention: 2-drug regimen 
Drug regimen: ZDV + 3TC 
Time from exposure to nPEP: ≤ 72 hours 
 
2016 nPEP Guidelines Update Page 80 of 91 
Completion of nPEP: ARV adherence declined from 64% at week 3 to 52% at week 4; 7 patients on nPEP experienced nausea at 3 weeks 
HIV seroconversions: No seroconversions to HIV, HBV, or HCV were noted in 44 children tested at 6 months 
Conclusion: Follow-up of patients after mass exposure was difficult and adherence to nPEP was poor. Fewer follow-up visits are probably adequate in a non-
mobile community (might consider eliminating the 3-month follow-up visit). 
Authors, year: Papenburg et al, 200865 
Type of study: Combination of prospective and retrospective case series describing community acquired needle stick injuries in children at 2 pediatric tertiary care 
teaching hospitals (1988–2006 for one hospital and 1995–2000 at another hospital) 
Location: Montreal, Canada 
Sample size: n = 274 pediatric patients with community acquired needlestick injuries; 73% of patients sought care on day of injury; n = 210 injuries occurred during 
an era when nPEP was available; n = 87 patients offered nPEP; n = 82 patients accepted nPEP 
Risk: CA-NSI; blood reported on needle or syringe in 36 injuries; n = 71 reported an injury that bled 
Intervention: 2-drug or 3-drug regimen 
Drug regimen: ZDV + 3TC (n = 74); ZDV + 3TC + NFV (n = 4); ZDV + 3TC + IDV (n = 3); ZDV + 3TC + RTV (n = 1) 
Time from exposure to nPEP: Not specified 
Completion of nPEP: 10/82 (12%) patients discontinued nPEP; unclear from report if remaining 72 completed the full 28-day course 
HIV seroconversions: 0 HIV seroconversions occurred at 6 month follow-up visit among 189/274 (nPEP and non-nPEP) patients tested for HIV 
Conclusion: There were no seroconversions for HIV, HBV, or HCV among the 274 pediatric, community-acquired needlestick injuries, adding evidence that 
suggests the risk of transmission of bloodborne viruses in these exposures is low. 
Authors, year: Russell et al, 200267 
Type of study: Prospective study of children with community-acquired needlestick injuries (published 2002) 
Location: Melbourne, Australia 
Sample size: n = 50 cases of CA-NSI; median age = 6.9 years (range, 1.8–14.3 years) 
Risk: CA-NSI 
Intervention: No nPEP offered 
Drug regimen: Not applicable 
Time from exposure to nPEP: Not applicable 
Completion of nPEP: Not applicable 
HIV seroconversions: No seroconversions among 36 children tested for HIV, HBC, HBC 
Conclusion: No seroconversions to HIV, HBV, or HCV occurred among 50 cases of CA-NSI; HBV prophylaxis and vaccination was administered and no nPEP 
for HIV was administered. 
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Authors, year: Thomas et al, 200664 
Type of study: Case report of CA-NSIs sustained by 21 children on primary school playground, including an HIV-infected source patient 
Location: London, England 
Sample size: n = 20 children exposed and started on nPEP; 1 child already known to be HIV infected at baseline, not started on nPEP 
Risk: CA-NSI 
Intervention: 3-drug regimen 
Drug regimen: ZDV + 3TC + NVP 
Time from exposure to nPEP: Within 72 hours 
Completion of nPEP: 10/20 (50%) 
HIV seroconversions: None 
Conclusion: Was logistically difficult to provide nPEP under such circumstances, however, it seemed to be effective. 
Mixed Populations Studies 
Authors, year: Babl et al, 200058 
Type of study: Retrospective medical record review of children and adolescents presenting with CA-NSI in to the pediatric emergency room of an urban hospital 
during June 1997–June 1998 
Location: Boston, Massachusetts 
Sample size: n = 10 pediatric and adolescent patients offered nPEP; n = 8 started on nPEP 
Risk: Sexual assault (n = 6); CA-NSI (n = 4) 
Intervention: 3-drug regimens 
Drug regimen: ZDV + 3TC+ Indinavir (n = 7); ZDV + 3TC+ NFV (n = 1) 
Time from exposure to nPEP:  
Completion of nPEP: 2/8 (25%) completed 28-day course; financial concerns, side effects, additional psychiatric and substance abuse issues, degree of parental 
involvement influenced adherence to nPEP and follow-up 
HIV seroconversions: No seroconversions among 5 tested at 4 to 28 weeks. 
Conclusion: HIV nPEP presented medical and management challenges and requires coordinated effort. Need for written protocol, coordinated approach, and 
national guidelines. 
Authors, year: Beymer et al, 201461 
Type of study: Retrospective medical record review of clients receiving PEP services at LGBT community-based clinic (May 2011–December 2012) 
Location: Los Angeles 
Sample size: n = 649 nPEP clients (n = 529 [81.5%] first PEP use, n = 120 [18.5%] PEP use 1–5 times previous to current nPEP initiation); whites, Hispanics, and 
blacks made up 42.5%, 35.4%, and 8.8% of nPEP users, and 30.4%, 42.4%, and 16.7% of HIV-infected persons, respectively 
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Risk: Gay/homosexual 75.5%, bisexual 11.9%, heterosexual 10.6%, other 1.9% 
Intervention: 2-drug regimen 
Drug regimen: TDF/FTC 
Time from exposure to nPEP: ≤ 72 hours; mean time from exposure to first PEP medication dose 38.5 hours (SD = 19 h) 
Completion of nPEP: 93% self-reported taking all 4 pills in the previous 4-day medication recall period at 2 weeks after nPEP initiation 
HIV seroconversions: 7 seroconversions occurred during the 6-month study period after nPEP initiation (including the 5 months after completing nPEP; exact 
timing not described) 
Conclusion: 18.5% repeat nPEP users may benefit from PrEP; racial/ethnic inequities found in nPEP use compared with corresponding HIV prevalence deserves 
attention. 
Authors, year: Bogoch et al, 201459 
Type of study: Prospective longitudinal study of referrals to nPEP programs in 2 emergency rooms and 2 academic medical centers 
Location: Boston, MA 
Sample size: n = 180 persons referred for nPEP; median age 28 years (interquartile range, 23–35 years); 65.6% women; n = 98 (54.4%) attended first nPEP visit 
Risk: Sexual (57.2%), 72% nonconsensual, 1% MSM; nonsexual (42.8%), 17.8% injecting-drug use, 40% accidental needlestick injuries, 42.2% accidental 
mucous membrane or non-needle percutaneous exposures 
Intervention: 3-drug regimen 
Drug regimen: First line regimen: co-formulated TDF and FTC (Truvada) and LPV/r (Kaletra); RAL was substituted for LPV/r with drug interactions or side 
effects preventing adherence 
Time from exposure to nPEP: Not reported 
Completion of nPEP: 43/177 (46%) patients had documented completion of a 28-day course of nPEP; women were less likely to complete a 28-day course of 
nPEP 
HIV seroconversions: Not reported 
Conclusion: There were significant attrition rates between the emergency department and nPEP follow-up clinic. Older patients and persons without insurance 
were significantly less likely to attend initial clinic for nPEP care after presenting to the emergency department. Individuals with exposure to a known HIV-
positive source individual were more likely to attend their initial clinic appointment. Women accounted for the majority of nonconsensual sexual exposures and 
were less likely to have documented completion of their 28-day nPEP regimen. 
Authors, year: Chan et al, 201352 
Type of study: Retrospective cohort study with medical record review at large urban hospital emergency room, January 1, 2008–December 31, 2010 
Location: Toronto, Canada 
Sample size: n = 241 patients 
Risk: All were sexual exposures; MSM 76.8%, heterosexual 23.2%, non-consensual 5.0% of 236 with documentation about whether sex was consensual; HIV-
positive source n = 102 
Intervention: 2-drug regimen (for lower risk exposures), 3-drug regimen (for higher risk exposures) 
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Drug regimen: Not specified 
Time from exposure to nPEP: ≤ 72 hours; among 205 with known timing of exposure: < 24 hr, 70 (34.1%); 24–48 hr, 68 (33.2%); 48–72 hr, 28 (13.7%); > 72 hr, 
7 (3.4%); not documented, 32 (15.6%) 
Completion of nPEP: Of 205 patients given nPEP, n = 71 (34.6%) completed a 28-day course; n = 20 (9.8%) stopped medications early due to patient preference, 
cost, low HIV risk, source patient tested HIV negative; n = 114 (55.6%) unknown completion status; n = 55 with adverse effects, diarrhea (n = 20), nonspecific 
gastrointestinal upset (n = 14), nausea (n = 13) 
HIV seroconversions: Two patients who initially tested HIV negative at baseline subsequently tested HIV-positive at 3-month and 6-month visits; data regarding 
ongoing sexual exposure was incomplete 
Conclusion: While it was encouraging that 92.6% of patients presented within the 72-hour window period, only 34.6% were known to have completed the full 28-
day course. It is unclear whether the 2 HIV seroconversions that occurred during the 3-month and 6-month follow-up visits were nPEP failures as sexual histories 
were incomplete during follow-up. 
Authors, year: Diaz-Brito et al, 201253 
Type of study: Open label randomized multicenter clinical trial comparing 2 nPEP regimens in patients presenting to emergency rooms in 6 urban hospitals 
Location: Barcelona, Spain 
Sample size: n = 255 patients presenting for nPEP evaluation randomized into ZDV/3TC + LPV/r twice daily arm (n = 131) or ZDV/3TC + atazanavir (n = 124) 
Risk: n = 200; nonoccupational n = 170 (85%); sexual n = 156 (78%); occupational n = 30 (1%) 
Intervention: 3-drug regimen 
Drug regimen: ZDV/3TC + LPV/r or ZDV/3TC + atazanavir 
Time from exposure to nPEP: Median interval between exposure and presentation = 18h (IQR 5–32); nonoccupational (median = 20 hours); occupational 
(median = 5 hours) 
Completion of nPEP: 64% completed 28-day course in both arms; 92% of patients reported taking > 90% of scheduled doses (without difference between arms); 
adverse events reported in 46% of patients (49% LPV/r arm and 43% atazanavir arm); gastrointestinal problems more common in LPV/r arm 
HIV seroconversions: 0 
Conclusion: Rate of completion was similar for both arms; almost 50% of patients of both arms suffered side effects. Strategies to improve adherence are needed. 
Authors, year: Fletcher et al, 201363 
Type of study: Prospective cohort study 
Location: Los Angeles, California 
Sample size: n = 35 patients; gay n = 30; not gay = 5; mean age = 34.1 years (SD 7.4) 
Risk: Not clearly defined; however, participants reported mean of 11.9 (SD 26.5) episodes of unprotected anal intercourse in past 6 months 
Intervention: 2-drug regimen 
Drug regimen: TDF + FTC (Truvada) 
Time from exposure to nPEP: ≤ 72 hours 
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Completion of nPEP: 25/35 (71.4%) completed the 28-day course; 48.6% took all 28 doses; 14.3% took > 90% of doses; at baseline, higher number of lifetime 
STDs and recent episodes of unprotected anal intercourse were associated with reductions in medication adherence 
HIV seroconversions: 1 (participant reported nonadherence to nPEP and multiple subsequent sexual exposures) 
Conclusion: There was a significant indirect association between sexual risk taking and nPEP adherence. Interventions to reduce sexual risk taking will reduce 
risk for HIV acquisition and may play a role in improving nPEP adherence. 
Authors, year: Gulholm et al, 201354 
Type of study: Retrospective medical record review at urban hospital sexual health clinic (1/2008–12/2011) 
Location: Sydney, Australia 
Sample size: n = 282 patients on 319 occasions presented for nPEP; n = 262 (94.3%) male 
Risk: n = 260 (99.2%) participants had homosexual exposure; of 319 presentations, 203 (63.6%) receptive unprotected anal intercourse, 87 (27.4%) insertive anal 
intercourse, 12 (3.8%) receptive vaginal intercourse, 5 (1.6%) penile-vaginal sexual assault, 5 (1.6%) receptive fellatio, 5 (1.6%) needlestick injuries, 4 (1.3%) 
needle-sharing episodes 
Intervention: 2-drug or 3-drug regimen 
Drug regimen: Mainly TDF/FTC-containing regimens; TDF + FTC (n = 136 [42.6%]), TDF + FTC + d4T (n = 149 [46.7%]) 
Time from exposure to nPEP: ≤ 72 hours; < 4 hours (16 [5.1%]), 4–12 hours (59 [19.0%]), 12–24 hours (82 [26.5%]), 24–48 hours (96 [31.0%]), 48–72 hours 
(57 [18.4%]) 
Completion of nPEP: 228/319 (71/%) completed nPEP; completion associated with reporting AEs and changing the nPEP regimen; adverse events associated 
with being prescribed a regimen other than TDF/FTC, younger age, earlier year of nPEP prescription, and changing the nPEP regimen 
HIV seroconversions: 2 seroconversions more than 6 months after NPEP due to ongoing high-risk behavior 
Conclusion: nPEP was appropriately targeted to highest risk patients. HIV seroconversions due to ongoing high-risk sexual behavior highlight importance of 
integrating counseling regarding safer sexual behaviors as an integral component of nPEP care. 
Authors, year: Jain et al, 201560 
Type of study: Retrospective longitudinal study of electronic medical records of nPEP users (1999–2013) 
Location: Boston, Massachusetts 
Sample size: n = 894 patients; n = 1,244 nPEP courses; mean age at PEP enrollment = 33.9 years 
Risk: MSM = 788; heterosexual = 91; sexual assault = 66; transgender = 15; injection drug use = 14; sexual exposure (non-assault) = 1,152 
Intervention: n = 927 TDF-based treatment regimen; N = 592 3-drug regimen 
Drug regimen: Either an AZT/3TC or TDF/FTC backbone with or without a third drug. 
Time from exposure to nPEP: ≤ 72 hours 
Completion of nPEP: 85.7% completion rate overall (463 of 540 with documented completion status); reasons for discontinuing: medication intolerance (48.1%) 
due to nausea (43.2%), diarrhea (13.5%), rash (13.5%), HIV negative partner (9.1%); increased completion rates associated with having HIV-infected partner or 
fewer drugs in regimen (2 vs.3)  
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HIV seroconversions: Not reported 
Conclusion: nPEP use increased over time. nPEP users demonstrated recurrent high-risk behavior. A defined group of nPEP users may benefit from earlier, 
targeted HIV risk-reduction and PrEP counseling. 
Authors, year: Mayer et al, 200856 
Type of study: Two phase 4 studies of TDF-containing regimens compared to historical controls who took ZDV-containing regimens 
Location: Boston, Massachusetts 
Sample size: n = 353 enrollees; n = 44 (TDF/FTC arm); n = 68 (TDF/3TC arm); control arms: n = 122 ZDV/3TC arm, n = 119 ZDV/3TC + 3rd drug arm 
Risk: Sexual exposure; TDF/FTC arm, n = 41 (93.2%) male (MSM/bisexual), n = 41 male (100%); TDF/3TC arm, n = 66 (97.1 %) male, n = 56 (82.4% 
MSM/bisexual); ZDV/3TC arm, n = 98 (80.3%) male; ZDV/3TC + 3rd drug arm, n = 88 (73.9%) 
Intervention: 3 separate 2-drug regimens and one 3-drug regimen; 1-, 2-, or 3-pill burden 
Drug regimen: TDF + 3TC, TDF + FTC, or ZDV + 3TC (with or w/o a PI) 
Time from exposure to nPEP: ≤ 72 hours 
Completion of nPEP: 42–87.5% completed nPEP (highest completion in TDF regimens): 72.7% (n = 32 TDF/FTV arm), 87.5% (n = 63 TDF/3TC arm), 42.1% 
(n = 53 ZDV/3TC arm), 38.8% (n = 50 ZDV/3TC + 3rd drug arm [3rd drug was mainly PI]) 
HIV seroconversions: In TDF arms, n = 0 seroconversions; in AZT arms, n = 3 (during or shortly after their course of nPEP); Note: Level of adherence in 
seroconverters not described. 
Conclusion: Participants taking TDF-containing regimens for nPEP demonstrated greater adherence and tolerability, with milder side effects than those taking 
ZDV-containing regimens. 
Authors, year: Mayer et al, 201257 
Type of study: Evaluation of a novel 3-drug nPEP regimen 
Location: Boston, MA 
Sample size: TDF-FTC-RAL arm (n = 100); control arms: TDF/FTV arm, n = 44; AZT/3TC +3rd drug arm, n = 119; overall age range, 18–61 years; males (73.9%–
100%—all arms); MSM/bisexual (70.5%–71.5% in TDF arms) 
Risk: Sexual exposure to HIV-infected partner or partner of unknown HIV status 
Intervention: 3-drug regimen; 2-pill burden 
Drug regimen: RAL + fixed dose combination TDF and FTC (Truvada) 
Time from exposure to nPEP: ≤ 72 hours 
Completion of nPEP: 57% (n = 57) completed TDF-FTC-RAL arm (an additional 27% completed a modified regimen.); 72.7% (n = 32) completed TDF/FTV arm; 
38.8% (n = 46) completed AZT/3TC arm 
HIV seroconversions: 0 
Conclusion: Tolerability to the 3-drug regimen, with integrase inhibitor, RAL, was high. The most common side effects were nausea and vomiting, diarrhea, 
abdominal discomfort, headache, and fatigue. 
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Authors, year: McDougal et al, 201462 
Type of study: Retrospective medical record abstraction of patients attending a publicly funded HIV clinic between 2000 and 2010 
Location: Seattle, Washington 
Sample size: 360 evaluated for nPEP; 324 prescribed nPEP; median age 30 years (range, 14 years–68 years) 
Risk: Among patients evaluated for nPEP: sexual exposures (928%), MSM (59%), sexual assault (22%) 
Intervention: 66% (n = 214) 3-drug regimen 
Drug regimen:  
Time from exposure to nPEP: 334/260 (93%) initiated ≤ 72 hours, 177/360 (49%) within 24 hours 
Completion of nPEP: 287/324 (89%) completed nPEP 
HIV seroconversions: n = 4; 2 tested positive at 2 and 5 months; 1 tested negative at baseline and 11 days and positive at 5 months; 1 tested positive at 12 months 
after nPEP initiation; adherence to nPEP and history of ongoing sexual exposures not described 
Conclusion: Must increase education and promotion of HIV prevention, including nPEP for populations who would benefit most. Established nPEP service sites 
may have added benefit of also serving as locations for HIV case-finding and PrEP referrals. 
Authors, year: Olowookere et al, 201051 
Type of study: Retrospective medical record abstraction of clients presenting for HIV nPEP at an antiretroviral therapy clinic during January 2005–December 
2006 
Location: Ibadan, Nigeria 
Sample size: n = 48 clients received nPEP; mean age 27.9 years ± 12.3 years (n = 6, < 15 years); about 1/3 were children and adolescents 
Risk: Nonoccupational exposures: sexual assault (50%); occupational exposures: needlesticks (25%), blood splash into mucous membranes (25%) 
Intervention: 3-drug regimen 
Drug regimen: Either ZDV + 3TC + 3rd drug or D4T + 3TC + 3rd drug; 3rd drug = EFV, IDV or LPV/r 
Time from exposure to nPEP: Not reported 
Completion of nPEP: 38/48 (79%) completed therapy 
HIV seroconversions: No seroconversions among 40 clients at 6 months of follow-up 
Conclusion: 24% of clients receiving nPEP could not complete therapy due to side effects. 
Authors, year: Pierce et al, 201145 
Type of study: Data linkage study using an nPEP service database and an HIV surveillance registry 
Location: Australia 
Sample size: n = 1,420 male nPEP recipients; age range, 14–78 years; median = 34.5 years 
Risk: Indirect data suggest most participants presenting for NPEP are MSM, but risk behaviors were not collected for these participants 
Intervention: Number of drugs in nPEP regimen not reported. 
Drug regimen: Not reported 
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Time from exposure to nPEP: ≤ 72 hours 
Completion of nPEP: Not reported 
HIV seroconversions: n = 3 nPEP related failures; n = 34 additional seroconversions > 6 months after nPEP initiation and deemed related to ongoing risk behavior 
Conclusion: Frequency of nPEP use was not associated with risk of HIV seroconversion. Note: Data on nPEP adherence and completion were not available, but 
may have provided an explanation for drug failure. 
Authors, year: Rey et al, 200846 
Type of study: Retrospective medical record abstraction of all consultations for nPEP in three consultation centers January 2001–December 2002 
Location: Southeastern France 
Sample size: n = 910 exposures; age range, 15–18 yr (5.9%), 19–35 yr (68.6%), 36–50 yr (21.4%), > 50 yr (4.1%); men = 60.4%; female = 39.2%; 
transsexual = 0.3%; n = 800 given initial nPEP prescription; n = 776 accepted nPEP; n = 527 received remaining nPEP prescription to complete 28-day course 
Risk: n = 910 sexual exposures, including 108 sexual assaults, 220 homosexual contacts among men 
Intervention: 2- or 3-drug regimen 
Drug regimen: Not reported 
Time from exposure to nPEP: nPEP given before and after the 72 hour window period 
Completion of nPEP: 355/776 (44%) who accepted nPEP completed 28-day course 
HIV seroconversions: 1 seroconversion occurred in a patient after completing nPEP but who presented > 72 hours after a high-risk exposure (not considered an 
nPEP failure) 
Conclusion: Follow-up rates were poor; strategies need to improve follow-up, including a tracking process and psychosocial support for youngest patients and 
survivors of sexual assault. 
Authors, year: Shoptaw et al, 200855 
Type of study: Biobehavioral HIV prevention intervention 
Location: Los Angeles 
Sample size: n = 100 enrollees 
Risk: High-risk sexual or drug-related exposure; n = 45 drug use, n = 1 injection drug use, n = 63 MSM, n = 9 bisexual, n = 9 heterosexual; mean age 31.8 years 
Intervention: 2-drug regimen; 1-pill burden 
Drug regimen: ZDV + 3TC 
Time from exposure to nPEP: ≤ 72 hours 
Completion of nPEP: n = 84 individuals received the full 28-day supply of study drug; 63/84 (75%) completed nPEP 
HIV seroconversions: 0 
Conclusion: nPEP provision for persons at high risk for HIV is feasible and safe at the community level. The most common adverse events were fatigue, nausea, 
headache, and gastrointestinal complaints. 
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Authors, year: Siika et al, 200947 
Type of study: Retrospective cohort study of electronic medical records of patients enrolled for HIV nonoccupational and occupational PEP during November 
2001–December 2006 (Note: Only results for nPEP patients summarized in this table) 
Location: Eldoret, Kenya 
Sample size: n = 355 nPEP exposures among children, adolescents, and adults; 100% accepted nPEP; n = 296 advised to continue nPEP after testing HIV negative 
at baseline 
Risk: Sexual assault (n = 292 [82%]; female adult [n = 189], female child [n = 91], male child [n = 15]); unprotected consensual sex, condom malfunction, human 
bites, exposure to body fluids of individuals suspected to be HIV infected, and barber cuts (n = 63 [18%]) 
Intervention: 3-drug regimen; 2- or 3-pill burden 
Drug regimen: D4T + 3TC + NVP; ZDV + 3TC + LPV/r (Note: Authors do not distinguish between ARVs used for nPEP or oPEP) 
Time from exposure to nPEP: Median time = 19 hours (range, 1–672 hours; 86% < 72 hours) 
Completion of nPEP: 104/296 (35%) completed nPEP. No statistically significant difference in reported side effects between NVP arm (21%) and LPR/r arm 
(14%) (P = 0.44). No difference in completion rates for two arms (P = 0.91). 1 death related to ARV-associated acute hepatitis associated with NVP arm. 
HIV seroconversions: 1 HIV seroconversion at 6 weeks after nPEP initiation using RNA PCR test among 129 patients; seroconversion occurred in sexually 
assaulted child who presented ≤ 4 hours of assault and completed nPEP. HIV ELISA tests were negative in 87 patients; however, child who seroconverted did not 
undergo ELISA testing as well. 
Conclusion: It is feasible to provide nPEP and oPEP in resource-constrained settings. Lack of HIV testing, delayed presentation, ARV discontinuation, and loss to 
follow-up are challenges in Western Kenya. Centralization of PEP services may improve coordination and supervision. 
Authors, year: Tissot et al, 201048 
Type of study: Retrospective medical record abstraction of nPEP administrations during 1998–2007 
Location: Lausanne, Switzerland 
Sample size: n = 1,233 consultations for potential HIV exposure; n = 910 exposures among 867 persons included in final analysis; n = 830 individuals requested 
nPEP at least once; n = 710 initiated nPEP; 64% male, median age 30 years (range, 14–87 years) 
Risk: 58% = heterosexual; 15% = homosexual; 6% = sexual assault; 20% = nonsexual (mainly CA-NSI or sharing of injection drug equipment) 
Intervention: 3-drug regimen 
Drug regimen: Mainly ZDV + 3TC + NFV (n = 548, 77%) or ZDV + 3TC + LPV/r (n = 108, 15%) 
Time from exposure to nPEP: 60% sought care ≤ 24 hours after exposure and 82% sought care ≤ 48 hours 
Completion of nPEP: 423/710 (60%) completed 28-day course; 396/620 (64%) for which data were available, reported side effects (mainly gastrointestinal 
disturbance and fatigue) 
HIV seroconversions: 2 seroconversions occurred during follow-up, not attributable to nPEP failures 
Conclusion: HIV testing in source persons avoided nPEP in 31% of exposures. 
Authors, year: Tosini et al, 201049 
Type of study: Multi-site prospective study to evaluate the tolerability of nPEP with TDF/FTC +LPV/r 
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Location: France 
Sample size: n = 249 men and women; mean age 31.5 years; n = 166 completed 28 days of PEP (tolerability good in 58%) 
Risk: Nonoccupational exposures: sexual intercourse n = 204 (82%), other n = 5 (2%); occupational exposures (n = 40) 
Intervention: One 3-drug regimen; 2-pill burden 
Drug regimen: TDF + FTC + LPV/r vs. historical controls taking ZDV containing regimens or TDF + ATV 
Time from exposure to nPEP: ≤ 48 hours 
Completion of nPEP: 166/188 (88%) 
HIV seroconversions: No HIV seroconversions were recorded during the study 
Conclusion: The TDF/FTC + LPV/r regimen proved easy to use, well-tolerated, and had less participants to discontinue medications secondary to adverse effects 
when compared with historical controls. The authors recommend this regimen as standard of care for HIV nPEP. Among those with ≥ 1 side effect, 78% diarrhea, 
78% asthenia, 59% nausea and/or vomiting. 
Authors, year: Wong et al, 201050 
Type of study: Observational study of nPEP use following nPEP protocol and guidelines development in one Canada province 
Location: Alberta, Canada 
Sample size: n = 174 persons received nPEP (135 females, 39 males); median age 24 years (range 4–69 years) 
Risk: Sexual assault (68%, n = 118), percutaneous (21%, n = 36), consensual sex (7%, n = 12), mucosal (3%, n = 5), other (0.6%, n = 1), not documented (1%, n = 2) 
Intervention: Primarily 2 and 3-drug regimens, one 4-drug regimen 
Drug regimen: Not explicitly reported; most regimens included ZDV 
Time from exposure to nPEP: 86% of cases ≤ 48 hours 
Completion of nPEP: 86/174 (49%) 
HIV seroconversions: 0 of 143 
Conclusion: The majority of nPEP cases were sexual assaults in young women. No seroconversions were observed, however, lack of follow-up and early 
discontinuation of medication were problematic. NPEP programs need to better address adherence and follow-up. 
Blood Transfusion Study 
Authors, year: Al-Hajjar et al, 201471 
Type of study: Case report of nPEP use following inadvertent HIV-infected blood transfusion 
Location: Riyadh, Saudi Arabia 
Sample size: One 12 year old girl with sickle cell disease 
Risk: Child was inadvertently transfused with large volume of HIV-infected packed red blood cells 
Intervention: 4-drug regimen 
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Drug regimen: TDF, FTC, DRV/r and RAL (DRV/r subsequently changed to LPV) 
Time from exposure to nPEP: At 24 hours after transfusion 
Completion of nPEP: Completed 13 weeks of ARV PEP 
HIV seroconversions: Patient did not seroconvert (negative for HIV-1 DNA and plasma HIV-1 RNA by PCR through 8 months following exposure) 
Conclusion: Authors report successful use of combination ART nPEP after a large volume transfusion of HIV-contaminated blood despite detection initially of 
HIV antibodies immediately after the transfusion. The fact that antibodies disappeared after nPEP initiation cautions against not starting or stopping nPEP in 
patients with detectable antibodies immediately after a contaminated blood transfusion.  
Abbreviations 
3TC, lamivudine; ATV, atazanavir; AZT, zidovudine; CA-NSI, community-acquired needlestick injury; d4T, stavudine; DRV/r, darunavir + ritonavir; ED, 
emergency department; ELISA, enzyme-linked immunosorbent assay; EFV, efavirenz; FTC, emtricitabine; HBV, hepatitis B virus; HCV, hepatitis C virus; HIV, 
human immunodeficiency virus; IDV, indinavir; LPV, lopinavir; LPV/r, lopinavir/ritonavir; MSM, men who have sex with men; NFV, nelfinavir; nPEP, 
nonoccupational postexposure prophylaxis; NVP, nevirapine; oPEP, occupational postexposure prophylaxis; PEP, postexposure prophylaxis; PI, protease inhibitor; 
PrEP, preexposure prophylaxis; RAL, raltegravir; RNA PCR, ribonucleic acid polymerase chain reaction; RPV, rilpivirine; SD, standard deviation; TDF, tenofovir 
disoproxil fumarate; ZDV, zidovudine. 
Trade-named Drug Compositions 
Combivir, ZDV+3TC; Kaletra, LPV/r (lopinavir + ritonavir); Truvada, TDF + FTC. 
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Appendix 4  
Consideration of Other Alternative HIV nPEP Antiretroviral Regimensa 
Create a combination regimen alternative to those in Table 5: May combine 1 drug or drug pair from Column A with 1 pair of 
nucleoside/nucleotide reverse transcriptase inhibitors from Column B.  
Or 
Use an existing fixed-dose combination alternative to those in Table 5. 
Prescribers unfamiliar with these medications should consult physicians familiar with the agents and their toxicities.  
Column A 
Raltegravir 
Darunavir + ritonavir  
Etravirine 
Rilpivirine  




Tenofovir DF+ emtricitabine 
Tenofovir DF + lamivudine 
Zidovudine + lamivudine 
Zidovudine + emtricitabine 
Fixed-dose combinations 
The fixed-dose combinations Stribild (elvitegravir, cobicistat, tenofovir DF, emtricitabine) and Complera (rilpivirine, tenofovir DF, and 
emtricitabine) are complete regimens and no additional antiretrovirals are needed. 












ANTIRETROVIRAL MEDICATIONS CONTRAINDICATED AS nPEP 
Nevirapine 
Efavirenz (not for pregnant women) 
Tenofovir (not for persons with eCrCl < 60 ml/min) 
Abbreviations: DF, disoproxil fumarate; eCrCl, estimated creatinine clearance; nPEP, nonoccupational postexposure prophylaxis; TM, trademark. 
a  These antiretrovirals can be considered for use in regimens alternative to those in Table 5. For detailed information on each drug, please refer to individual drug 
package inserts available at: AIDSInfo Drugs Database at: http://aidsinfo.nih.gov/drugs. For consultation or assistance with HIV nPEP, contact PEPline 
(telephone 888-448-4911; internet site: http://www.nccc.ucsf.edu/about_nccc/pepline/). 
 
